Роль Гут Микробиота в неврологических, психиатрических и неевроразвитых расстройствах.

1. Introduction

The genetic heritage and environmental interactions of all microorganisms in a defined environment that colonize the human gastrointestinal system are defined as the gut microbiome (GMe). Instead, the term gut microbiota (GM) represents the set of all individual microorganisms, from bacteria to fungi, to protozoa to viruses [ 1 ]. The GM, along with the oral microbiota, presents the widest composition of microorganisms both qualitatively and quantitatively. Some oral diseases can affect both the airway and the GM. It is important to keep oral pathogens at the lowest possible load [ 2 , 3 , 4 , 5 ]. Several microorganisms have long been recognized as the causative agents of disease. Gastrointestinal pathogens such as Salmonella spp. or Clostridioides difficile are entrenched in public awareness, while research into the effects of the beneficial bacteria of the GM has been overshadowed until recently [ 6 , 7 , 8 , 9 ]. By increasing knowledge of its role, the GM has added a new dimension to the long-standing view that the mere presence of a single pathogenic microorganism leads to a given disease. For example, C. difficile can be found in up to 14% of healthy, asymptomatic individuals, while it appears to be a stable member of the eubiosi GM community [ 10 , 11 , 12 ]. In healthy individuals, the abundance and pathogenicity of the bacterium may be suppressed by the majority presence of a diverse microorganism composition the GM [ 13 , 14 , 15 ]. C. difficile infection is almost always preceded by broad-spectrum antibiotic therapy (usually for an unrelated issue), which causes a drastic reduction in ecosystem diversity, after which C. difficile can proliferate uncontrollably and become infectious [ 16 , 17 , 18 , 19 ]. The pathogenesis of C. difficile is a clear example of the importance of a dynamic GM, although there are many other studies linking abnormalities in the GM’s unhealthy microorganism diversity (dysbiosis) to a wide range of diseases [ 20 ]. In many of these cases, there is insufficient evidence to distinguish between coincidence and causation with the heterogeneity of the GM community within each individual and between individuals, making comparisons difficult. While alterations in the GM have been identified in several diseases and disorders, the physiological consequences of these changes are difficult to define, making it difficult to link them more definitively to the disease process. This is particularly true in cases of systemic diseases and may be even more so when considering psychiatric diagnoses such as schizophrenia [ 21 , 22 , 23 , 24 , 25 ]. Indeed, C. difficile infection can have a significant impact on feelings of anxiety and depression. However, the ability of GM to interact with the host’s nervous system could suggest a hitherto unrecognized link between the GM and neurological and psychological disease and disorders, and there is some evidence from research on both C. difficile and ulcerative colitis [ 26 , 27 , 28 ]. Current research suggests that alteration of the GM is associated with human health and disease, such as altered fat storage, associated with metabolic syndrome (such as obesity), cancer and other [ 29 , 30 , 31 , 32 ]. A pathological shift in the delicate balance of bacteria normally found in the gut encourages inflammatory responses, while beneficial bacteria (probiotics) promote anti-inflammatory properties and immune modulation [ 33 , 34 ]. For example, the relationship between GM, both beneficial and pathological, and autism symptomatology has been investigated in recent years, while gastrointestinal symptoms are commonly reported. Given the increasing prevalence of autism spectrum disorders and gastrointestinal problems, possibly related to pathological GM, combined with the immunological importance of vital bacteria and their importance for health, it is important to investigate the possible association between autism and the GM [ 35 , 36 , 37 ].

2. Methodology of Searching

The literature review was conducted over the last 10 years, between 2014 and 2024, using the scientific platforms PubMed, Scopus, and Web of Science. The search was aimed at identifying relevant studies on the interaction between GM and neurological and neuropsychiatric diseases, with a focus on the GM–brain axis (GBA). The following keywords were used: gut microbiota, GM-brain axis, dysbiosis, neurodevelopmental disorders, Parkinson’s disease, and mental health. These were combined with Boolean operators (AND, OR) to refine the results.

Inclusion criteria included original articles and reviews published in English within the last 10 years with a focus on the relationship between GM and neurological or neuropsychiatric disorders. Non-peer-reviewed articles, opinion pieces, and conference abstracts were excluded.

The search initially yielded 800 articles. After a review of titles and abstracts for relevance, 574 articles were subjected to full reading. Eventually, 228 publications were included in the review for their scientific relevance and significant contribution to the topic.

Identification: Records identified through database searching: 800

Screening: Records screened (titles and abstract): 800 Records excluded: 226 (800–574)

Eligibility: Full-text articles assessed for eligibility: 574 Full-text articles excluded (off-topic): 348

Included: Studies included in qualitative synthesis: 228

3. Objectives

The article discusses several key aspects of the GBA and its implications. Firstly, it explores the bidirectional communication between the central nervous system (CNS), autonomic nervous system (ANS), enteric nervous system (ENS), and hypothalamic–pituitary–adrenal axis (HPA), highlighting the importance of this network in influencing both mental and physical well-being. Another topic addressed is the role of the gut microbiota in producing neurotransmitters such as serotonin, dopamine, catecholamines, GABA, and ATP, demonstrating how intestinal bacteria can directly affect brain chemistry. The article delves into specific bacterial species that can modulate the GBA through the production of neurotransmitters or similar molecules, emphasizing the interconnectedness between the GM and brain functions. It also examines the link between gut dysbiosis and various neurological and psychiatric disorders, including Parkinson’s disease, multiple sclerosis, depression, schizophrenia, and bipolar disorder, showing how intestinal health can influence these pathological conditions. Lastly, attention is given to developmental neurological disorders, such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). In this context, factors related to GM, including composition and intestinal permeability, are explored as having a significant role in their development. Overall, the article covers five main research areas, offering a comprehensive and detailed overview of the importance of the GM in brain functions and neurological disorders. (1) GM Composition and Influencing Factors: exploration of how factors like diet, antibiotics, birth mode, and geography affect GM diversity and balance. (2) GBA and Biochemical Interactions: analysis of the bidirectional communication between GM and the nervous system, emphasizing the role of neurotransmitters, SCFAs, and the HPA axis in health and disease. (3) Neurological and Psychiatric Disorders: examination of GM’s role in the pathogenesis of conditions such as Parkinson’s disease, autism, ADHD, depression, and schizophrenia. (4) Therapeutic Strategies: evaluation of emerging treatments targeting GM modulation, including probiotics, prebiotics, and fecal microbiota transplantation. (5) Health Implications of GM Dysbiosis: discussion of the consequences of GM imbalances, including its links to metabolic, immune, and inflammatory disorders.

4. Discussion

4.1. Composition of Human Gut Microbiota

The human GM is estimated to consist of 10–100 trillion microorganisms together with the genes of their cells. The totality of this genome is estimated at 3.3 million genes, compared to approximately 22,000 genes in the human body [ 3 , 38 , 39 ]. There is about 99.9% identity of the human genome, but there may be 70–90% variation among the microorganisms’ genomes of different individuals [ 15 , 40 , 41 , 42 , 43 ]. The genetic complement of the GM, or in other words, the set of “microorganisms (eukaryotic archaea, bacteria and viruses), the genetic information they carry and the environment in which they interact”, is believed to exceed that of the human genome by 100 times [ 4 , 44 , 45 ]. Until recently, the main method of isolating and recording the microorganisms of the GM was their culture [ 46 , 47 , 48 , 49 , 50 ]. the various bacteria are classified into Gram positive and Gram negative, depending on the ability of their cell wall to retain the pigment or not after treatment with alcohol [ 51 , 52 , 53 ]. The GM remains relatively stable throughout life, with average changes. Its basic constitution is formed in the early years [ 54 , 55 ]. The commonly accepted theory so far is that the gastrointestinal system of the newborn is sterile, but also, several studies found that the microorganisms pass to the fetus through the placenta, umbilical cord, and amniotic fluid, but this remains under debate [ 56 , 57 , 58 ]. In the first months of life, anaerobic microorganisms predominate, mainly, Bacteroides, Bifidobacterium , and species from the Lactobacillaceae family, which are classified in the phyla Bacteroidota , Bacillota , and Actinomycetota , respectively. Pseudomonadota is also added from breast milk. Studies show that approximately 28% of bacteria in infants comes from breast milk. Later, with the introduction of other different aliments (from ages 5 months to 2 years), bacteria of the Ruminococcaceae and Lachnospiraceae families, which belong to the Bacillota phyla, also appear in the GM. Around the age of 2 or 3 years, strains of the Verrucomicrobia phylum are also found. From around the age of 5, the GM of children begins to resemble that of adults ( Figure 1 and Figure 2 ) [ 59 , 60 , 61 , 62 ].

Studies have shown that the GM of adolescents still has some differences compared to that of adults. These differences are found at the level of the bacterial genus and mainly concern Bifidobacterium , which appears at almost twice the percentage compared to adults ( Figure 3 ). Credits: Original figure by I.A. Charitos [ 63 , 64 , 65 ].

In adults, the main phyla of the GM are Bacillota and Bacteroidota , which account for 90% of the GM. Actinomycetota , Pseudomonadota , Fusobacteriota , and Verrucomicrobiota are found in smaller percentages. The genus Clostridium accounts for 95% of the Bacillota and the remainder is represented by the genera Bacillus , Enterococcus , and Ruminococcus and the Lactobacillaceae family. Bacteroidetes consists mainly of Bacteroides and Prevotella , while the main genus of Actinomycetota is the Bifidobacterium . Everyone’s GM displays different clusters of microorganisms that shape everyone’s intestinal microbiota type. The enterotype is specific and stable for each person throughout his life, and in the case of change, it returns to the original composition. The most important difference between these types lies in the way energy is produced from the available elements of the intestinal content. The intestine types seem to be determined by eating habits, mainly during childhood age ( Figure 4 ) [ 66 , 67 , 68 , 69 ].

4.2. The Main Factors That Affect the Gut Microbiota’s Composition

Several factors influence the composition of the GM. In neonates and infants, gestational age at birth plays a significant role. Premature birth results in delayed intestinal colonization, with limited microbiome diversity, reduced Bifidobacterium and Bacteroides , and an increase in potentially pathogenic bacteria such as Enterobacteriaceae . Breastfeeding is also affected by prematurity, impacting the composition of the GM [ 70 , 71 , 72 ]. The mode of birth further influences GM. During natural labor, the newborn is colonized by maternal microbiota including Prevotella , Sneathia , Bifidobacterium longum , and others, alongside organisms such as Escherichia coli , Staphylococcus , Bacteroides fragilis , and Streptococcus . In contrast, cesarean-section births lead to colonization by hospital-associated microorganisms like Staphylococcus and Corynebacterium , with reduced diversity and the absence of Escherichia , Shigella , and Bacteroides [ 73 , 74 , 75 , 76 ]. Diet and feeding mode also significantly affect the GM composition. Breastfeeding promotes healthier GM, characterized by increased Bifidobacterium spp. and decreased C. difficile and E. coli . The quality of breast milk is influenced by maternal gut health during pregnancy [ 77 , 78 ]. Age-related changes in diet lead to variations in GM. Adults over 70, for example, experience changes linked to dietary monotony and inflammatory conditions. Furthermore, geographic and cultural differences in diet contribute to GM variations, with diet being a key regulator of microbiota composition. Specific bacteria, including Latilactobacillus sakei and Faecalibacterium prausnitzii , are affected by diet, and obesity and BMI also play a crucial role in altering the GM composition, particularly in children. Obese children show increased Bacillota and decreased Bacteroidota , while variations in BMI result in microbiota differences [ 79 , 80 , 81 , 82 , 83 , 84 ]. In cases of conditions such as anorexia nervosa, significant changes in GM occur, with an increase in Enterobacteriaceae and Methanobrevibacter smithii , and a decrease in Roseburia, Ruminococcus , and Clostridium [ 85 , 86 , 87 ]. Furthermore, the use of antibiotics and xenobiotics, and drug abuse, has a substantial impact on GM. The type of antibiotic, dosage, and administration period affect microbiota composition. Macrolides, for example, decrease Actinomycetota and increase Bacteroides and Bacillota , while Penicillin and Clarithromycin have similar, though less severe, effects. The misuse of antibiotics, particularly in early childhood, has been linked to reduced microbiota diversity and the development of allergic diseases such as asthma and food allergies, largely influenced by specific strains of the Clostridia genus [ 88 , 89 , 90 , 91 , 92 , 93 ].

Furthermore, it has been proven that negative changes (dysbiosis) in the composition of the GM (are related also to several pathological conditions [ 94 , 95 , 96 , 97 ]. As we mentioned, deviations from a healthy lifestyle directly affect the GM and are related to many metabolic diseases (unhealthy gut metabolome), which, in turn, can lead to an exacerbation of symptoms or new-onset neurocognitive disorders. It must be mentioned that the first association of various diseases with the intestine is attributed to the father of medicine Hippocrates [ 94 , 98 , 99 , 100 , 101 ].

4.3. The GBA Biochemical Interactions

Until recently, studies on the GBA focused on digestion and satiety. In recent years, however, emphasis has been placed on the degree of influence of higher functions, psychological state, and behavior by GBA communication [ 102 , 103 , 104 , 105 ]. Several research efforts are constantly being made in the direction of correlating various brain functions with GM. Animal studies more directly indicate the GBA communication [ 106 , 107 , 108 , 109 , 110 ]. The GM–brain axis includes the central nervous system (CNS), the autonomic nervous system (ANS), the enteric nervous system (ENS), the hypothalamic–pituitary–adrenal axis (HPA), and their neurotransmitters. The ANS collects information from the ENS and, through its sympathetic and parasympathetic branches, conveys it to the CNS. Conversely, it carries impulses from the CNS to the periphery. The HPA axis functions as a key regulator of the body’s response to various stressful situations [ 111 ]. The ENS is connected to the ANS, but also to the peripheral nervous system (PNS), and controls the behavior of the gastrointestinal tract, specifically, its motility, local blood flow, and absorbency, but also the secretions of the intestinal mucosa, and regulates endocrine and immune function [ 112 , 113 ]. Enteric neurons are connected to the ANS but do not have a direct neuronal connection with the CNS. They are organized in microcircuits, which receive stimuli from local factors and can respond to them directly, without the mediation of the CNS. Nevertheless, there is usually communication between the two systems—through neural circuits, which initially connect the ENS to the ANS and, indirectly, to the CNS—and one affects the other [ 114 , 115 , 116 ]. The ANS consists of sympathetic and parasympathetic nervous systems. The sympathetic nervous system is related to the control of gut motility, intestinal mucosal secretions, and vascular regulation by depressing the ENS and through the direct vasoconstriction of his action. The main neurotransmitters of the sympathetic nervous system are, in addition to noradrenaline (NE), neuropeptide Y (NPY) and ATP. The parasympathetic nervous system is mainly represented by the pneumogastric (or vagus) nerve [ 117 , 118 , 119 , 120 ]. The pneumogastric nerve is the 10th cranial nerve and its action on the gastrointestinal tract is related to food intake, digestion, the maintenance of the gastrointestinal barrier, and immunity. More specifically, the endings of the pneumogastric nerve in the intestinal mucosa act as chemoreceptors and are activated by hormones, peptides, and other elements, which release the endothelial and neuroendocrine cells of the intestine [ 121 , 122 , 123 ]. At the same time, the mechanoreceptors of the pneumogastric nerve sense the distension of the gastrointestinal tract. The result of these stimuli is causing an increase in the secretion of gastric fluids, insulin, and glucagon, with an effect on the digestion process. The pneumogastric nerve contributes to the maintenance of the intestinal barrier mainly by activating the mucus cells in the intestinal wall and strengthening the connections between them [ 124 , 125 ]. Finally, inflammatory mediators such as cytokines and chemical mediators from mast cells, but also several pathogens, activate the pneumogastric nerve. The result is the activation of the cholinergic anti-inflammatory pathway, in which stimuli carried by the pneumogastric nerve, mediated by acetylcholine, regulate the action of macrophages around inflammation [ 126 , 127 , 128 ]. The HPA axis is part of the limbic system, which is associated with emotion and memory. The HPA axis, with its complexity of endocrine pathways, plays a regulatory role in the response to stressful situations, but also in metabolism, immune responses, and the ANS [ 129 , 130 ]. In response to stressful situations, the hypothalamus secretes adrenocorticotrophic hormone-releasing factor (CRF), which causes the pituitary to release adrenocorticotropin-releasing hormone (ACTH), which leads to the secretion of cortisol from the adrenal glands [ 131 ]. Glucocorticoids that enter the circulation mobilize energy reserves, activate lipolysis and, through the mediation of the ANS, lead to vasoconstriction, and are, therefore, a consequence of the response to the stress-inducing stimulus and, therefore, to the psychological state ( Figure 5 ) [ 129 , 132 ].

4.4. The Bacteria Neurotransmitters

An important role in the GBA connection is also played by a multitude of chemicals, which act as neurotransmitters. Many of these neurotransmitters are, in turn, linked to the GMe. Among the most important neurotransmitters are catecholamines (adrenaline, noradrenaline, and dopamine), serotonin, γ-aminobutyric acid (GABA) and adenosine triphosphatase (ATP), and histamine [ 133 , 134 ]. Serotonin is synthesized in the midbrain, specifically, in its nucleus seam. Recent research, however, has shown that some of it is also synthesized in intestinal nerves along the intestinal tract. Serotonin’s precursor is tryptophan, an amino acid derived from proteins that are consumed in foods such as meat, dairy, and fruit. Serotonin then binds to its various receptors with the corresponding effect [ 135 ]. Certain GM bacterial species, such as E. coli , are thought to be able to use tryptophan as well, indirectly reducing serotonin levels [ 136 , 137 ]. Besides serotonin, tryptophan is also a precursor of kynurenic acid. It seems that GM also plays a role in determining the direction that the metabolism of tryptophan will take, thus influencing the adequacy or lack of serotonin in the body [ 138 ]. Serotonin’s relationship with the gut is also indirectly demonstrated by the fact that drugs such as selective serotonin reuptake inhibitors, in addition to their action on the CNS, also affect several symptoms of chronic diseases of the gastrointestinal tract [ 139 , 140 ]. The basic precursor of all catecholamines is the amino acid L-tyrosine, which is first converted into L-dopa by the enzyme tyrosine hydroxylase and then into dopamine. The main regulator of the action of tyrosine hydroxylase is endogenous neuropeptide Y (NPY). Dopamine is the first catecholamine in the production chain and is mainly synthesized in the CNS [ 141 , 142 ]. Adrenaline and noradrenaline are synthesized either locally in the postganglionic nerve fibers of the sympathetic system or centrally in the adrenal glands. Each of the catecholamines binds to specific receptors. Noradrenaline decreases blood flow to the gut and adrenaline increases it. The action of dopamine depends on its concentration, as in low doses, it causes vasodilation, and in high doses, it causes vasoconstriction [ 143 , 144 ]. The participation of catecholamines in the regulation of gut motility is expressed by its reduction by adrenaline and, conversely, its increase by noradrenaline. In addition to the perfusion and motility of the intestine, adrenaline and noradrenaline also affect the absorption of nutrients [ 145 , 146 ]. Dopamine, on the other hand, seems to be less involved in the absorption of various substances, but is related to the reward and satisfaction system after digestion. Studies show that dopamine’s involvement in the reward system is directly regulated by stimuli from the gastrointestinal tract. New evidence shows that catecholamines are also involved in the immune mechanism of the gut, but not in the expected way. It seems that these substances reduce the immune response of the intestinal mucosa and increase the “aggressiveness” of different bacteria [ 147 ]. Adenosine triphosphatase (ATP), in addition to being a basic source of energy, also has a role as a neurotransmitter. Although its relationship to the GBA is not clear, its receptors have been identified along the intestinal tract, and in areas of gut inflammation, the concentration of ATP is increased. GABA is the main inhibitory neurotransmitter of the CNS. In the gastrointestinal tract, however, the action of GABA is reversed as it mainly causes stimulation. Its action is mainly related to intestinal peristalsis and immunity [ 148 , 149 ].

4.5. Bacteria That Affect GM–Brain Axis

Several studies conclude that GM bacteria, in addition to influencing neurotransmitters and their precursors, also secrete factors with a similar effect. For example, members of the genera Candida , Streptococcus , Escherichia , and Enterococcus have been shown to secrete serotonin, members of Escherichia, Bacillus , and Saccharomyces produce dopamine and noradrenaline, members of the genus Lactobacillus produce acetylcholine, and Bifidobacterium synthesizes GABA [ 150 , 151 ]. In addition to the above, the bacteria of the GM also secrete several other substances. Some of these substances, although not neurotransmitters in the strict sense of the term, act in a similar way to the nervous system. Among these substances are those from the bacteria metabolism such as short-chain fatty acids (SCFAs), with butyric, propionic, and acetic acid as main representatives, which have a particularly important position [ 152 , 153 ]. The SCFAs have a protective local effect on the intestine, as they contribute to its integrity, mucus production, and intestinal immunity. The blood–brain barrier is crossed by SCFAs; moreover, they are isolated in the cerebrospinal fluid, exerting a neuroprotective effect, and are possibly involved in neurodevelopmental and neurodegenerative processes [ 152 , 154 ].

For example, propionic acid is produced mainly by Bacteroidota , Bacillota , and Lachnospiraceae , while butyric acid is produced by Faecalibacterium prausnitzii , Eubacterium rectale , Eubacterium hallii , Coprococcus comes , and Coprococcus eutactus . In conclusion, the function of the GM–brain axis appears to be based on four mechanisms. The first is the impulses carried from the periphery to the brain via the pneumogastric nerve and spinal nerves. The following is the stimuli that are conveyed through cytokines and the various 23 types of hormones. The last mechanism is the action of the derivatives of the GM microorganisms themselves, either directly in the brain through the blood circulation, or indirectly by affecting intermediate mechanisms [ 155 , 156 , 157 ].

4.6. Gut Microbiota and Neurological and Psychiatric Diseases and Disorders

In recent years, the studies that associate disturbances in the intestinal microbiome and, by extension, in the gut–brain axis, with various pathological conditions are increasing. Relatively recently, interest has also shifted towards neurological, psychiatric, and neurodevelopmental disorders, which are possibly influenced by variations in the GM [ 158 ]. Suspicion of the influence of the GBA on psychiatric diseases has been around for quite some time. The relationship between stress and the GMe is bidirectional [ 159 ]. Studies have shown that stress can alter GM through the activation of the HPA and the autonomic nervous system (ANS). Conversely, it is now proven that changes in GM can cause or limit stress in the body [ 160 , 161 ]. Most relevant studies have been carried out in animal models. For example, it has been shown that in germ-free rodents, the addition of a specific species of Bifidobacteria led to increased activation of the stress-relevant stress axis. The introduction of Lactiplantibacillus plantarum had the opposite effect by reducing anxiety [ 162 , 163 ]. Parkinson’s disease is another neurological condition that is beginning to be associated with the GM composition. It is a neurodegenerative disease mainly characterized by the loss of dopaminergic neurons in the substantia nigra of the brain, accompanied by the accumulation of α-synuclein in the neurons [ 164 , 165 , 166 ]. There is now evidence to support the appearance of α-synucleinopathy (αS-pathy) already in the initial stages of the disease in the ENS [ 167 ]. Patients experience gastrointestinal disturbances due to increased intestinal permeability due to the reduced concentration of SCFAs. The composition of the GM in patients with Parkinson’s disease shows significant differences. Specifically, there is an increase mainly in Bifidobacterium , Akkermansia , Oscillibacter , Alistipes , and the Lactobacillaceae family and a decrease in Roseburia , Fusicatenibacter , and Faecalibacterium , which produce butyric acid and have an anti-inflammatory effect. The association of Parkinson’s disease with changes in the GM paves the way for studies in other alpha-synucleinopathies such as Alzheimer’s disease [ 168 , 169 , 170 ]. Multiple sclerosis is an inflammatory disease of the CNS of immune etiology. Of the neurological diseases that have been associated to some extent with GM, some indicative ones are mentioned [ 171 ]. Comparisons of GM in multiple sclerosis patients and healthy individuals show differences not so much in qualitative as in quantitative composition, with some populations of microorganisms appearing in greater or lesser numbers. More specifically, the population of Akkermansia muciniphila appears proportionally increased in patients with multiple sclerosis in recent research. The Akkermansia has been linked to inflammatory pathways and the activation of the complement system [ 172 ]. This connection of multiple sclerosis with the composition of the GM has opened new therapeutic avenues and related research is constantly being carried out [ 173 ]. The link between depression and bowel disorders has been identified for quite some time, although the exact mechanism has not yet been confirmed. Among the pathophysiological mechanisms that have been proposed is the one related to permeability of the intestinal mucosa. According to this mechanism, stressful situations affect the intestinal epithelial barrier, resulting in an increase in its permeability [ 174 ].

This allows Gram-negative bacteria to meet the ENS and immune cells. An immune response is induced with accumulation of inflammation factors. Accumulated cytokines lead to the stimulation of the pneumogastric nerve, which, in turn, activates the HPA axis, resulting in mood disorders [ 175 , 176 , 177 , 178 ]. At the same time, in patients with depression, a decrease in the diversity and differentiation of the GM and a predominance of Bacillota , Bacteroidota , and Actinomycetota [ 179 , 180 , 181 ] has been observed. Schizophrenia and the relationship with GM disturbances is a relatively new field of research. Inflammatory processes have been shown to be involved in the pathophysiology of the disease [ 182 , 183 , 184 ]. Disturbances in GM may alter the permeability of the intestinal wall and, thus, contribute to inflammation, through the action of cytokines [ 98 , 185 ]. At the same time, bacterial species that produce butyric acid have been identified in reduced concentrations in schizophrenia. Finally, the confirmed action of GM derivatives on the hematological barrier can explain the enhancement of CNS inflammation in disorders of its composition [ 186 ]. The existence of an inflammatory process of the CNS in schizophrenia has now been proven. Specific changes in the GM, such as a reduction in α-diversity markers, have been documented in patients with schizophrenia. Bacteria such as Veillonellaceae and Lachnospiraceae have been associated with disease severity. Differences in GM composition have also been identified in schizophrenia patients before and after receiving treatment [ 187 ]. Bipolar disorder affects approximately 40 million people worldwide and is mainly expressed by mood swings [ 188 , 189 ]. The relationship of the disease with gastrointestinal disorders such as irritable bowels has long been proven. Patients with bipolar disorder show evidence of peripheral inflammation with an increase in cytokines during disease flares. Also, inflammatory processes seem to coexist with changes in tryptophan metabolism in these patients. These changes, as already mentioned, are also related to the action of the GM [ 190 ]. More specifically, there is a decrease in the populations of microorganisms such as Faecalibacterium , and an increase in the populations of the Lactobacillaceae family and Enterococcus , as well as Actinomycetota phyla . At the same time, the pharmaceutical preparations used to treat bipolar disorder have also been shown to affect the balance between the individual populations of GM. In this way, the relationship between the change in the composition of the GM and the manifestation of bipolar disorder is indirectly demonstrated [ 191 ].

4.7. Gut Microbiota and Neurodevelopmental Disorders

The neurodevelopmental disorders include ASD, intellectual disability, attention deficit hyperactivity disorder (ADHD), communication disorders, developmental motor disorders including tics, and specific learning disabilities [ 192 ]. The most sensitive periods for the appearance of neurodevelopmental disorders are considered the fetal period, childbirth, the breastfeeding period, and, in general infancy. During this period, factors such as stress, eating habits, and the mother’s endocrinological and immune status, but also the composition of the mother’s gut and vaginal microbiota, as well as the route of delivery, can affect the development of the child’s CNS, leading or not to the appearance of neurodevelopmental disorders [ 193 , 194 ]. In ADHD, hypermobility with changes in the composition of the GM appeared in the literature much more recently, and mainly after the corresponding studies concerning autism spectrum disorders. Most of these theories are since several conditions associated with the onset of ADHD in a person are also associated with changes in the GM. Given the function of the GBA, as already mentioned, a theoretical etiological model for ADHD is created [ 195 , 196 , 197 ]. More specifically, the relationship between the mode of birth and ADHD has already been suggested through the increased rates of its occurrence in people born by the caesarean section. Research indicates that children born by caesarean section may have a higher risk of developing ADHD compared to those born via vaginal delivery. The mode of birth affects the initial colonization of the newborn’s gut microbiota, which plays a crucial role in neurodevelopment [ 198 , 199 , 200 ]. Infants are exposed to different microbial environments than those born vaginally, potentially impacting the gut–brain axis. Additionally, the stress response during vaginal delivery triggers the release of hormones that aid brain development, a process that might be less pronounced in caesarean section births. Perinatal factors, such as complications during labor that necessitate emergency CS, are also linked to an increased risk of ADHD. While there is evidence suggesting a link between caesarean section and ADHD, the relationship is complex and influenced by multiple factors, necessitating further research to clarify the underlying mechanisms. Increased rates of the disorder are also found in people who were born prematurely, as well as in people who did not breastfeed in their newborn age. There are also studies linking ADHD to taking certain antibiotics at a young age [ 200 , 201 , 202 , 203 ]. However, these studies are not proof of the relationship, as there is a large degree of discrepancy between them. Indeed, in a cohort study in twins suggests that there is no association between ADHD and ASD diagnoses and early-life antibiotic use when environmental and genetic family factors are considered. Finally, in a population-based cohort study, the results suggest that early life antibiotic exposure has minimal impact on the risk of ASD and/or ADHD. Thus, the risk increase should not postpone reasonable antibiotic use. What could be taken as a conclusion is that the age of taking antibiotics plays a role in the later onset of ADHD, with a greater burden at younger ages. All the conditions are also related to changes in GM, thus raising the question of the association of ADHD with these changes [ 204 , 205 , 206 ] ( Table 1 ).

Of all the neurodevelopmental disorders, the appearance of ASD has been most extensively linked to the presence of changes in GM. Years of observations have linked gastrointestinal disorders to autism. More specifically, increased incidence rates of diarrheal stools, constipation, flatulence, etc. have been demonstrated. The link between autism and inflammatory bowel disease has also been described in these individuals, which is called “autistic enterocolitis” [ 207 ]. At the same time, disturbances in the permeability of the intestine have been observed in people with ASD, resulting in the increased absorption of pathogenic substances such as endotoxemia with neurotoxins. Changes in the composition and balance among the various microorganisms of the GM appear to be related to the ASD phenotype [ 208 , 209 ]. A series of studies and meta-analyses in animal models and in humans in recent years has tried to prove the existence of this relationship, with particularly encouraging results. Regarding the composition of the GM, studies have shown an increase in the populations of Bacillota phyla, compared to those of Bacteroidota phyla , with a simultaneous decrease in Alistipes , Bilophila , Prevotella , and Veillonella and a significant increase in Collinsella , Corynebacterium , and the lactobacillaceae family in individuals with ASD. An increase has also been observed in the microbial populations of Clostridium and Akkermansia species in children with ASD compared to normal individuals [ 210 , 211 , 212 ]. Also, according to one study, bacteria of the genus Desulfovibrio were detected in almost half of the subjects with ASD and almost none in the normal subjects. Although the existence and, even more so, the nature, of a causal relationship between changes in the GM and autism has not been proven with certainty, several theories have been proposed in this direction [ 213 ]. Most theories concerning environmental influences focus on the fetal and perinatal period. Infections during pregnancy, and mainly, febrile infections with antipyretics, have been described in the prenatal history of individuals with autism [ 214 , 215 ]. Also, caesarean birth has been confirmed in a percentage of around 12–13% of people with ASD. This mode of birth alters the microbial colonization of the newborn, as instead of the normal microorganism of the mother’s vagina, the newborn is colonized mainly with skin microbiota [ 216 ]. The mode of birth affects the newborn’s initial microbiota colonization. Babies born by caesarean section are primarily colonized with skin microbiota, which can lead to GM imbalances (dysbiosis). This dysbiosis may influence neurodevelopment and is associated with an increased risk of ASD. The altered microbiota can affect gut permeability, immune system development, and the production of microbial metabolites, potentially contributing to ASD symptoms. Further research is needed to understand these mechanisms fully. Reference is also made to the administration of antibiotic substances both to the mother during pregnancy and to the newborn in the perinatal period. Antibiotic use has been shown to alter the GM, but there is insufficient evidence to demonstrate the permanence of these changes [ 217 ]. Alterations in the GM in individuals with ASD may cause rivalries between different strains, resulting in a reduction in microorganism diversity and function in the GM. Various metabolites and/or conjugates/derivatives of the microorganisms may change their action with the change in diversity in the GM, or the GM may be weakened, resulting in the appearance of the corresponding symptoms [ 218 , 219 ]. For example, the Clostridia species produces a substance, namely, 3-(3-hydroxyphenyl)-3 hydroxypropionic acid, which is considered harmful, as it reduces the concentrations of catecholamines. This substance is found to be elevated in autism and is blamed for the appearance of symptoms such as stereotypies in animal research models. Studies linking autism to the GM have paved the way for therapeutic interventions aimed at the GM could possibly reduce autism symptoms [ 220 ]. Probiotics are live bacteria that are found in various foods and their intake has several positive effects on the body. Specific species of probiotics, such as Bacteroides fragilis , have been shown in animal studies to improve behavioral disturbances, stereotypies, and anxiety symptoms often seen in ASD. Similar results are obtained from studies also in animals with the administration of some species of the Lactobacillaceae family [ 221 , 222 , 223 ]. Prebiotics are non-digestible nutritional substances, which serve as “food” for the non-pathogenic strains of the GM. Administration of prebiotics to people with autism, usually in combination with probiotics, had positive effects on the symptoms of the disorder. Taking certain antibiotics, such as vancomycin and metronidazole, had similar results, probably due to the limitation of PathoBact in the intestinal tract [ 224 , 225 ]. A more ambitious approach to treating ASD through the GM is transfer therapy and the transplantation of fecal microorganism (fecal microbial transplant) [ 226 , 227 , 228 ]. Although numerous studies have suggested an association between alterations in the GM and the symptoms of ASD, there is still no conclusive evidence demonstrating a direct causal link in humans, so further research is required.

5. Conclusions

The present study highlights several key findings regarding the GBA, which refers to the interactions between the central nervous system, the gastrointestinal system, and the microorganisms that live in the intestinal tract. Existing studies, including those in pediatric populations such as children with autism, suggest that changes in the GM could indeed be related to gastrointestinal disorders. This provides a rationale for why gastrointestinal disorders commonly occur in children with autism. Specific bacterial taxa, such as increased populations of Bacillota and decreased populations of Bacteroidota , have been identified in individuals with ASD. Other notable changes include increased levels of Clostridium and Akkermansia species. While similar changes in GM composition have been observed in ADHD, the evidence is less consistent. Further research is needed to determine if the same bacterial species are associated with both ASD and ADHD. GM dysbiosis can lead to conditions affecting mood, causing anxiety, depression, and other neuropsychiatric symptoms. While numerous studies suggest associations between GM changes and neurodevelopmental disorders, definitive causal relationships, especially in humans, have not been established. Many findings are based on animal models, and extrapolating these results to humans requires caution. The GM shows variability from person to person under normal conditions. Large-scale systematic studies with clinical correlations are needed to understand how to effectively modify GM for therapeutic purposes. Overall, the study of the GM holds promise for future therapeutic and diagnostic possibilities, including the use of potential biomarkers in various diseases and disorders. However, further research is essential to translate these findings into clinical practice.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Author Contributions

Conceptualization, I.A.C., G.D., F.I., A.M.I., A.D.I. and L.F.; methodology, I.A.C., L.F., G.D., A.P., A.D.I. and F.I.; software, A.P., A.C. and S.S.; validation, A.M.I., L.F. and A.P.; formal analysis, F.I.; resources, I.A.C., F.C. and S.S.; data curation, G.D. and A.C.; writing—original draft preparation, I.A.C., A.D.I. and F.I.; writing—review and editing, G.D., F.C. and A.C.; visualization, A.M.I.; supervision, F.I.; project administration, S.S. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

Authors declare no conflicts of interest.

Abbreviations

References

1. Colella M. Charitos I.A. Ballini A. Cafiero C. Topi S. Palmirotta R. Santacroce L. Microbiota Revolution: How Gut Microbes Regulate Our Lives World J. Gastroenterol. 2023 29 4368 4383 10.3748/wjg.v29.i28.4368 37576701 PMC10415973

2. Santacroce L. Passarelli P.C. Azzolino D. Bottalico L. Charitos I.A. Cazzolla A.P. Colella M. Topi S. Godoy F.G. D’Addona A. Oral Microbiota in Human Health and Disease: A Perspective Exp. Biol. Med. Maywood 2023 248 1288 1301 10.1177/15353702231187645 37688509 PMC10625343

3. Ursell L.K. Metcalf J.L. Parfrey L.W. Knight R. Defining the Human Microbiome Nutr. Rev. 2012 70 (Suppl. 1) S38 S44 10.1111/j.1753-4887.2012.00493.x 22861806 PMC3426293

4. Thursby E. Juge N. Introduction to the Human Gut Microbiota Biochem. J. 2017 474 1823 1836 10.1042/BCJ20160510 28512250 PMC5433529

5. Bengmark S. Ecological Control of the Gastrointestinal Tract. The Role of Probiotic Flora Gut 1998 42 2 7 10.1136/gut.42.1.2 9505873 PMC1726957

6. Sehgal K. Khanna S. Gut Microbiome and Clostridioides Difficile Infection: A Closer Look at the Microscopic Interface Ther. Adv. Gastroenterol. 2021 14 1756284821994736 10.1177/1756284821994736 PMC7905718 33747125

7. Seekatz A.M. Safdar N. Khanna S. The Role of the Gut Microbiome in Colonization Resistance and Recurrent Clostridioides Difficile Infection Ther. Adv. Gastroenterol. 2022 15 17562848221134396 10.1177/17562848221134396 36425405 PMC9679343

8. Lavoie T. Appaneal H.J. LaPlante K.L. Advancements in Novel Live Biotherapeutic Products for Clostridioides Difficile Infection Prevention Clin. Infect. Dis. 2023 77 S447 S454 10.1093/cid/ciad639 38051964

9. Davis C.D. The Gut Microbiome and Its Role in Obesity Nutr. Today 2016 51 167 174 10.1097/NT.0000000000000167 27795585 PMC5082693

10. Ozaki E. Kato H. Kita H. Karasawa T. Maegawa T. Koino Y. Matsumoto K. Takada T. Nomoto K. Tanaka R. Clostridium Difficile Colonization in Healthy Adults: Transient Colonization and Correlation with Enterococcal Colonization J. Med. Microbiol. 2004 53 167 172 10.1099/jmm.0.05376-0 14729940

11. Fredheim E.G.A. Klingenberg C. Rohde H. Frankenberger S. Gaustad P. Flaegstad T. Sollid J.E. Biofilm Formation by Staphylococcus Haemolyticus J. Clin. Microbiol. 2009 47 1172 1180 10.1128/JCM.01891-08 19144798 PMC2668337

12. Berg R.D. Bacterial Translocation from the Gastrointestinal Tract Trends Microbiol. 1995 3 149 154 10.1016/S0966-842X(00)88906-4 7613757

13. Van den Abbeele P. Belzer C. Goossens M. Kleerebezem M. De Vos W.M. Thas O. De Weirdt R. Kerckhof F.-M. Van de Wiele T. Butyrate-Producing Clostridium Cluster XIVa Species Specifically Colonize Mucins in an in Vitro Gut Model ISME J. 2013 7 949 961 10.1038/ismej.2012.158 23235287 PMC3635240

14. Inchingolo F. Tatullo M. Abenavoli F.M. Marrelli M. Inchingolo A.D. Villabruna B. Inchingolo A.M. Dipalma G. Severe Anisocoria after Oral Surgery under General Anesthesia Int. J. Med. Sci. 2010 7 314 318 10.7150/ijms.7.314 20922052 PMC2948214

15. Aggarwal N. Kitano S. Puah G.R.Y. Kittelmann S. Hwang I.Y. Chang M.W. Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies Chem. Rev. 2023 123 31 72 10.1021/acs.chemrev.2c00431 36317983 PMC9837825

16. Dethlefsen L. Huse S. Sogin M.L. Relman D.A. The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing PLoS Biol. 2008 6 e280 10.1371/journal.pbio.0060280 19018661 PMC2586385

17. Mada P.K. Alam M.U. Figure, Impression Smear of Clostridioides Difficile Available online: https://www.ncbi.nlm.nih.gov/books/NBK431054/figure/article-19632.image.f3/ (accessed on 24 November 2024)

18. Corriero A. Giglio M. Soloperto R. Inchingolo F. Varrassi G. Puntillo F. Microbial Symphony: Exploring the Role of the Gut in Osteoarthritis-Related Pain. A Narrative Review Pain Ther. 2024 13 409 433 10.1007/s40122-024-00602-9 38678155 PMC11111653

19. Dethlefsen L. McFall-Ngai M. Relman D.A. An Ecological and Evolutionary Perspective on Human-Microbe Mutualism and Disease Nature 2007 449 811 818 10.1038/nature06245 17943117 PMC9464033

20. Bien J. Palagani V. Bozko P. The Intestinal Microbiota Dysbiosis and Clostridium Difficile Infection: Is There a Relationship with Inflammatory Bowel Disease? Ther. Adv. Gastroenterol. 2013 6 53 68 10.1177/1756283X12454590 PMC3539291 23320050

21. von Bartheld C.S. Myths and Truths about the Cellular Composition of the Human Brain: A Review of Influential Concepts J. Chem. Neuroanat. 2018 93 2 15 10.1016/j.jchemneu.2017.08.004 28873338 PMC5834348

22. Topi S. Bottalico L. Charitos I.A. Colella M. Di Domenico M. Palmirotta R. Santacroce L. Biomolecular Mechanisms of Autoimmune Diseases and Their Relationship with the Resident Microbiota: Friend or Foe? Pathophysiology 2022 29 507 536 10.3390/pathophysiology29030041 36136068 PMC9505211

23. Dipalma G. Inchingolo A.D. Inchingolo F. Charitos I.A. Di Cosola M. Cazzolla A.P. Focus on the Cariogenic Process: Microbial and Biochemical Interactions with Teeth and Oral Environment J. Biol. Regul. Homeost. Agents 2021 35 429 440 10.23812/20-747-A 33904270

24. Imfeld T. Nutrition, diet and dental health--de- and remineralisation of teeth Ther. Umsch. Rev. Ther. 2008 65 69 73 10.1024/0040-5930.65.2.69 18517060

25. Abrams G.D. Pathogenesis of Gastrointestinal Infections Am. J. Surg. Pathol. 1988 12 (Suppl. 1) 76 81 3354762

26. Ullah H. Arbab S. Tian Y. Liu C. Chen Y. Qijie L. Khan M.I.U. Hassan I.U. Li K. The Gut Microbiota–Brain Axis in Neurological Disorder Front. Neurosci. 2023 17 1225875 10.3389/fnins.2023.1225875 37600019 PMC10436500

27. Abdel-Haq R. Schlachetzki J.C.M. Glass C.K. Mazmanian S.K. Microbiome–Microglia Connections via the Gut–Brain Axis J. Exp. Med. 2019 216 41 59 10.1084/jem.20180794 30385457 PMC6314531

28. Alaish S.M. Smith A.D. Timmons J. Greenspon J. Eyvazzadeh D. Murphy E. Shea-Donahue T. Cirimotich S. Mongodin E. Zhao A. Gut Microbiota, Tight Junction Protein Expression, Intestinal Resistance, Bacterial Translocation and Mortality Following Cholestasis Depend on the Genetic Background of the Host Gut Microbes 2013 4 292 305 10.4161/gmic.24706 23652772 PMC3744514

29. Bäckhed F. Manchester J.K. Semenkovich C.F. Gordon J.I. Mechanisms Underlying the Resistance to Diet-Induced Obesity in Germ-Free Mice Proc. Natl. Acad. Sci. USA 2007 104 979 984 10.1073/pnas.0605374104 17210919 PMC1764762

30. Fahed G. Aoun L. Bou Zerdan M. Allam S. Bou Zerdan M. Bouferraa Y. Assi H.I. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021 Int. J. Mol. Sci. 2022 23 786 10.3390/ijms23020786 35054972 PMC8775991

31. Prasun P. Mitochondrial Dysfunction in Metabolic Syndrome Biochim. Biophys. Acta Mol. Basis Dis. 2020 1866 165838 10.1016/j.bbadis.2020.165838 32428560

32. Inchingolo F. Inchingolo A.D. Palumbo I. Trilli I. Guglielmo M. Mancini A. Palermo A. Inchingolo A.M. Dipalma G. The Impact of Cesarean Section Delivery on Intestinal Microbiota: Mechanisms, Consequences, and Perspectives—A Systematic Review Int. J. Mol. Sci. 2024 25 1055 10.3390/ijms25021055 38256127 PMC10816971

33. Wu H.-J. Wu E. The Role of Gut Microbiota in Immune Homeostasis and Autoimmunity Gut Microbes 2012 3 4 14 10.4161/gmic.19320 22356853 PMC3337124

34. Inchingolo F. Inchingolo A.M. Avantario P. Settanni V. Fatone M.C. Piras F. Di Venere D. Inchingolo A.D. Palermo A. Dipalma G. The Effects of Periodontal Treatment on Rheumatoid Arthritis and of Anti-Rheumatic Drugs on Periodontitis: A Systematic Review Int. J. Mol. Sci. 2023 24 17228 10.3390/ijms242417228 38139057 PMC10743440

35. Alharthi A. Alhazmi S. Alburae N. Bahieldin A. The Human Gut Microbiome as a Potential Factor in Autism Spectrum Disorder Int. J. Mol. Sci. 2022 23 1363 10.3390/ijms23031363 35163286 PMC8835713

36. Chernikova M.A. Flores G.D. Kilroy E. Labus J.S. Mayer E.A. Aziz-Zadeh L. The Brain-Gut-Microbiome System: Pathways and Implications for Autism Spectrum Disorder Nutrients 2021 13 4497 10.3390/nu13124497 34960049 PMC8704412

37. Saurman V. Margolis K.G. Luna R.A. Autism Spectrum Disorder as a Brain-Gut-Microbiome Axis Disorder Dig. Dis. Sci. 2020 65 818 828 10.1007/s10620-020-06133-5 32056091 PMC7580230

38. Kwong W.K. Moran N.A. Evolution of Host Specialization in Gut Microbes: The Bee Gut as a Model Gut Microbes 2015 6 214 220 10.1080/19490976.2015.1047129 26011669 PMC4615251

39. Corriero A. Giglio M. Inchingolo F. Moschetta A. Varrassi G. Puntillo F. Gut Microbiota Modulation and Its Implications on Neuropathic Pain: A Comprehensive Literature Review Pain Ther. 2024 13 33 51 10.1007/s40122-023-00565-3 38087070 PMC10796891

40. Logsdon G.A. Vollger M.R. Eichler E.E. Long-Read Human Genome Sequencing and Its Applications Nat. Rev. Genet. 2020 21 597 614 10.1038/s41576-020-0236-x 32504078 PMC7877196

41. Pottie I. Vázquez Fernández R. Van de Wiele T. Briers Y. Phage Lysins for Intestinal Microbiome Modulation: Current Challenges and Enabling Techniques Gut Microbes 2024 16 2387144 10.1080/19490976.2024.2387144 39106212 PMC11305034

42. Brüssow H. Infection Therapy: The Problem of Drug Resistance- and Possible Solutions Microb. Biotechnol. 2017 10 1041 1046 10.1111/1751-7915.12777 28737021 PMC5609240

43. Inchingolo F. Inchingolo A.M. Malcangi G. De Leonardis N. Sardano R. Pezzolla C. de Ruvo E. Di Venere D. Palermo A. Inchingolo A.D. The Benefits of Probiotics on Oral Health: Systematic Review of the Literature Pharmaceuticals 2023 16 1313 10.3390/ph16091313 37765121 PMC10534711

44. Lin L. Zhang J. Role of Intestinal Microbiota and Metabolites on Gut Homeostasis and Human Diseases BMC Immunol. 2017 18 2 10.1186/s12865-016-0187-3 28061847 PMC5219689

45. Tanemoto S. Sujino T. Kanai T. Intestinal immune response is regulated by gut microbe Nihon Rinsho Meneki Gakkai Kaishi 2017 40 408 415 10.2177/jsci.40.408 29367525

46. Wang Z. Zolnik C.P. Qiu Y. Usyk M. Wang T. Strickler H.D. Isasi C.R. Kaplan R.C. Kurland I.J. Qi Q. Comparison of Fecal Collection Methods for Microbiome and Metabolomics Studies Front. Cell. Infect. Microbiol. 2018 8 301 10.3389/fcimb.2018.00301 30234027 PMC6127643

47. Flores R. Shi J. Yu G. Ma B. Ravel J. Goedert J.J. Sinha R. Collection Media and Delayed Freezing Effects on Microbial Composition of Human Stool Microbiome 2015 3 33 10.1186/s40168-015-0092-7 26269741 PMC4534027

48. Walters K.E. Martiny J.B.H. Alpha-, Beta-, and Gamma-Diversity of Bacteria Varies across Habitats PLoS ONE 2020 15 e0233872 10.1371/journal.pone.0233872 32966309 PMC7510982

49. Fierer N. Leff J.W. Adams B.J. Nielsen U.N. Bates S.T. Lauber C.L. Owens S. Gilbert J.A. Wall D.H. Caporaso J.G. Cross-Biome Metagenomic Analyses of Soil Microbial Communities and Their Functional Attributes Proc. Natl. Acad. Sci. USA 2012 109 21390 21395 10.1073/pnas.1215210110 23236140 PMC3535587

50. Inchingolo A.M. Patano A. Piras F. Mancini A. Inchingolo A.D. Paduanelli G. Inchingolo F. Palermo A. Dipalma G. Malcangi G. Interconnection between Microbiota-Gut-Brain Axis and Autism Spectrum Disorder Comparing Therapeutic Options: A Scoping Review Microorganisms 2023 11 1477 10.3390/microorganisms11061477 37374979 PMC10303020

51. Kim B.-R. Shin J. Guevarra R. Lee J.H. Kim D.W. Seol K.-H. Lee J.-H. Kim H.B. Isaacson R. Deciphering Diversity Indices for a Better Understanding of Microbial Communities J. Microbiol. Biotechnol. 2017 27 2089 2093 10.4014/jmb.1709.09027 29032640

52. Thomas A.M. Jesus E.C. Lopes A. Aguiar S. Begnami M.D. Rocha R.M. Carpinetti P.A. Camargo A.A. Hoffmann C. Freitas H.C. Tissue-Associated Bacterial Alterations in Rectal Carcinoma Patients Revealed by 16S rRNA Community Profiling Front. Cell. Infect. Microbiol. 2016 6 179 10.3389/fcimb.2016.00179 28018861 PMC5145865

53. Li G. Yang M. Zhou K. Zhang L. Tian L. Lv S. Jin Y. Qian W. Xiong H. Lin R. Diversity of Duodenal and Rectal Microbiota in Biopsy Tissues and Luminal Contents in Healthy Volunteers J. Microbiol. Biotechnol. 2015 25 1136 1145 10.4014/jmb.1412.12047 25737115

54. Zhang Y. Wei C. Guo C.-C. Bi R.-X. Xie J. Guan D.-H. Yang C.-H. Jiang Y.-H. Prognostic Value of microRNAs in Hepatocellular Carcinoma: A Meta-Analysis Oncotarget 2017 8 107237 107257 10.18632/oncotarget.20883 29291025 PMC5739810

55. Li J. Lin C. Zhou X. Zhong F. Zeng P. Yang Y. Zhang Y. Yu B. Fan X. McCormick P.J. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332 J. Virol. 2022 96 e02013-21 10.1128/jvi.02013-21 35389231 PMC9044943

56. Santacroce L. Man A. Charitos I.A. Haxhirexha K. Topi S. Current Knowledge about the Connection between Health Status and Gut Microbiota from Birth to Elderly. A Narrative Review Front. Biosci. Landmark Ed. 2021 26 135 148 10.52586/4930 34162042

57. Russo R. Cristiano C. Avagliano C. De Caro C. La Rana G. Raso G.M. Canani R.B. Meli R. Calignano A. Gut-Brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases Curr. Med. Chem. 2018 25 3930 3952 10.2174/0929867324666170216113756 28215162

58. Sun M.-F. Shen Y.-Q. Dysbiosis of Gut Microbiota and Microbial Metabolites in Parkinson’s Disease Ageing Res. Rev. 2018 45 53 61 10.1016/j.arr.2018.04.004 29705121

59. Yao Y. Cai X. Ye Y. Wang F. Chen F. Zheng C. The Role of Microbiota in Infant Health: From Early Life to Adulthood Front. Immunol. 2021 12 708472 10.3389/fimmu.2021.708472 34691021 PMC8529064

60. Goodrich J.K. Davenport E.R. Beaumont M. Jackson M.A. Knight R. Ober C. Spector T.D. Bell J.T. Clark A.G. Ley R.E. Genetic Determinants of the Gut Microbiome in UK Twins Cell Host Microbe 2016 19 731 743 10.1016/j.chom.2016.04.017 27173935 PMC4915943

61. Kreutz A. Chang X. Hogberg H.T. Wetmore B.A. Advancing Understanding of Human Variability through Toxicokinetic Modeling, in Vitro-in Vivo Extrapolation, and New Approach Methodologies Hum. Genom. 2024 18 129 10.1186/s40246-024-00691-9 PMC11580331 39574200

62. Hiruki T. Fernandes B. Ramsay J. Rother I. Acute Typhlitis in an Immunocompromised Host. Report of an Unusual Case and Review of the Literature Dig. Dis. Sci. 1992 37 1292 1296 10.1007/BF01296575 1499455

63. Agans R. Rigsbee L. Kenche H. Michail S. Khamis H.J. Paliy O. Distal Gut Microbiota of Adolescent Children Is Different from That of Adults FEMS Microbiol. Ecol. 2011 77 404 412 10.1111/j.1574-6941.2011.01120.x 21539582 PMC4502954

64. Rigsbee L. Agans R. Shankar V. Kenche H. Khamis H.J. Michail S. Paliy O. Quantitative Profiling of Gut Microbiota of Children with Diarrhea-Predominant Irritable Bowel Syndrome Am. J. Gastroenterol. 2012 107 1740 1751 10.1038/ajg.2012.287 22986438

65. Malcangi G. Patano A. Ciocia A.M. Netti A. Viapiano F. Palumbo I. Trilli I. Guglielmo M. Inchingolo A.D. Dipalma G. Benefits of Natural Antioxidants on Oral Health Antioxidants 2023 12 1309 10.3390/antiox12061309 37372039 PMC10294804

66. Arumugam M. Raes J. Pelletier E. Le Paslier D. Yamada T. Mende D.R. Fernandes G.R. Tap J. Bruls T. Batto J.-M. Enterotypes of the Human Gut Microbiome Nature 2011 473 174 180 10.1038/nature09944 21508958 PMC3728647

67. Liang C. Tseng H.-C. Chen H.-M. Wang W.-C. Chiu C.-M. Chang J.-Y. Lu K.-Y. Weng S.-L. Chang T.-H. Chang C.-H. Diversity and Enterotype in Gut Bacterial Community of Adults in Taiwan BMC Genom. 2017 18 932 10.1186/s12864-016-3261-6 28198673 PMC5310273

68. de Moraes A.C.F. Fernandes G.R. da Silva I.T. Almeida-Pititto B. Gomes E.P. Pereira A.d.C. Ferreira S.R.G. Enterotype May Drive the Dietary-Associated Cardiometabolic Risk Factors Front. Cell. Infect. Microbiol. 2017 7 47 10.3389/fcimb.2017.00047 28280715 PMC5322172

69. Turnbaugh P.J. Ley R.E. Hamady M. Fraser-Liggett C.M. Knight R. Gordon J.I. The Human Microbiome Project Nature 2007 449 804 810 10.1038/nature06244 17943116 PMC3709439

70. Beharry K.D. Latkowska M. Valencia A.M. Allana A. Soto J. Cai C.L. Golombek S. Hand I. Aranda J.V. Factors Influencing Neonatal Gut Microbiome and Health with a Focus on Necrotizing Enterocolitis Microorganisms 2023 11 2528 10.3390/microorganisms11102528 37894186 PMC10608807

71. Inchingolo A.M. Gargiulo Isacco C. Inchingolo A.D. Nguyen K.C.D. Cantore S. Santacroce L. Scacco S. Cirulli N. Corriero A. Puntillo F. The Human Microbiota Key Role in the Bone Metabolism Activity Eur. Rev. Med. Pharmacol. Sci. 2023 27 2659 2670 10.26355/eurrev_202303_31803 37013784

72. Gregory K.E. Samuel B.S. Houghteling P. Shan G. Ausubel F.M. Sadreyev R.I. Walker W.A. Influence of Maternal Breast Milk Ingestion on Acquisition of the Intestinal Microbiome in Preterm Infants Microbiome 2016 4 68 10.1186/s40168-016-0214-x 28034306 PMC5200970

73. Suárez-Martínez C. Santaella-Pascual M. Yagüe-Guirao G. Martínez-Graciá C. Infant Gut Microbiota Colonization: Influence of Prenatal and Postnatal Factors, Focusing on Diet Front. Microbiol. 2023 14 1236254 10.3389/fmicb.2023.1236254 37675422 PMC10478010

74. Adamczak A.M. Werblińska A. Jamka M. Walkowiak J. Maternal-Foetal/Infant Interactions-Gut Microbiota and Immune Health Biomedicines 2024 12 490 10.3390/biomedicines12030490 38540103 PMC10967760

75. Inchingolo A.D. Dipalma G. Palmieri G. Di Pede C. Semjonova A. Patano A. Ceci S. Cardarelli F. Montenegro V. Garibaldi M. Functional Breastfeeding: From Nutritive Sucking to Oral Health J. Biol. Regul. Homeost. Agents 2022 36 121 137 10.23812/j.biol.regul.homeost.agents.202236.2S3.12

76. Luckey T.D. Introduction to Intestinal Microecology Am. J. Clin. Nutr. 1972 25 1292 1294 10.1093/ajcn/25.12.1292 4639749

77. Fouhy F. Ross R.P. Fitzgerald G.F. Stanton C. Cotter P.D. Composition of the Early Intestinal Microbiota: Knowledge, Knowledge Gaps and the Use of High-Throughput Sequencing to Address These Gaps Gut Microbes 2012 3 203 220 10.4161/gmic.20169 22572829 PMC3427213

78. Kelsen J.R. Wu G.D. The Gut Microbiota, Environment and Diseases of Modern Society Gut Microbes 2012 3 374 382 10.4161/gmic.21333 22825455 PMC3463495

79. Bolte L.A. Vich Vila A. Imhann F. Collij V. Gacesa R. Peters V. Wijmenga C. Kurilshikov A. Campmans-Kuijpers M.J.E. Fu J. Long-Term Dietary Patterns Are Associated with pro-Inflammatory and Anti-Inflammatory Features of the Gut Microbiome Gut 2021 70 1287 1298 10.1136/gutjnl-2020-322670 33811041 PMC8223641

80. Turpin W. Dong M. Sasson G. Raygoza Garay J.A. Espin-Garcia O. Lee S.-H. Neustaeter A. Smith M.I. Leibovitzh H. Guttman D.S. Mediterranean-Like Dietary Pattern Associations With Gut Microbiome Composition and Subclinical Gastrointestinal Inflammation Gastroenterology 2022 163 685 698 10.1053/j.gastro.2022.05.037 35643175

81. Zhang Z. Taylor L. Shommu N. Ghosh S. Reimer R. Panaccione R. Kaur S. Hyun J.E. Cai C. Deehan E.C. A Diversified Dietary Pattern Is Associated With a Balanced Gut Microbial Composition of Faecalibacterium and Escherichia/Shigella in Patients With Crohn’s Disease in Remission J. Crohns Colitis 2020 14 1547 1557 10.1093/ecco-jcc/jjaa084 32343765

82. Houtman T.A. Eckermann H.A. Smidt H. de Weerth C. Gut Microbiota and BMI throughout Childhood: The Role of Firmicutes, Bacteroidetes, and Short-Chain Fatty Acid Producers Sci. Rep. 2022 12 3140 10.1038/s41598-022-07176-6 35210542 PMC8873392

83. Zhang S. Dang Y. Roles of Gut Microbiota and Metabolites in Overweight and Obesity of Children Front. Endocrinol. 2022 13 994930 10.3389/fendo.2022.994930 36157438 PMC9492854

84. Inchingolo A.M. Patano A. Di Pede C. Inchingolo A.D. Palmieri G. de Ruvo E. Campanelli M. Buongiorno S. Carpentiere V. Piras F. Autologous Tooth Graft: Innovative Biomaterial for Bone Regeneration. Tooth Transformer ® and the Role of Microbiota in Regenerative Dentistry. A Systematic Review J. Funct. Biomater. 2023 14 132 10.3390/jfb14030132 36976056 PMC10058341

85. Borgo F. Riva A. Benetti A. Casiraghi M.C. Bertelli S. Garbossa S. Anselmetti S. Scarone S. Pontiroli A.E. Morace G. Microbiota in Anorexia Nervosa: The Triangle between Bacterial Species, Metabolites and Psychological Tests PLoS ONE 2017 12 e0179739 10.1371/journal.pone.0179739 28636668 PMC5479564

86. Prochazkova P. Roubalova R. Dvorak J. Kreisinger J. Hill M. Tlaskalova-Hogenova H. Tomasova P. Pelantova H. Cermakova M. Kuzma M. The Intestinal Microbiota and Metabolites in Patients with Anorexia Nervosa Gut Microbes 2021 13 1 25 10.1080/19490976.2021.1902771 PMC8018350 33779487

87. Yu D. Nguyen S.M. Yang Y. Xu W. Cai H. Wu J. Cai Q. Long J. Zheng W. Shu X.-O. Long-Term Diet Quality Is Associated with Gut Microbiome Diversity and Composition among Urban Chinese Adults Am. J. Clin. Nutr. 2021 113 684 694 10.1093/ajcn/nqaa350 33471054 PMC7948864

88. Kesavelu D. Jog P. Current Understanding of Antibiotic-Associated Dysbiosis and Approaches for Its Management Ther. Adv. Infect. Dis. 2023 10 20499361231154443 10.1177/20499361231154443 36860273 PMC9969474

89. Sitkin S. Lazebnik L. Avalueva E. Kononova S. Vakhitov T. Gastrointestinal Microbiome and Helicobacter Pylori: Eradicate, Leave It as It Is, or Take a Personalized Benefit-Risk Approach? World J. Gastroenterol. 2022 28 766 774 10.3748/wjg.v28.i7.766 35317277 PMC8891730

90. Chiu C.-Y. Chan Y.-L. Tsai M.-H. Wang C.-J. Chiang M.-H. Chiu C.-C. Gut Microbial Dysbiosis Is Associated with Allergen-Specific IgE Responses in Young Children with Airway Allergies World Allergy Organ. J. 2019 12 100021 10.1016/j.waojou.2019.100021 30937143 PMC6439417

91. Chiu C.-Y. Chan Y.-L. Tsai M.-H. Wang C.-J. Chiang M.-H. Chiu C.-C. Su S.-C. Cross-Talk between Airway and Gut Microbiome Links to IgE Responses to House Dust Mites in Childhood Airway Allergies Sci. Rep. 2020 10 13449 10.1038/s41598-020-70528-7 32778700 PMC7417544

92. Inchingolo A.D. Inchingolo A.M. Malcangi G. Avantario P. Azzollini D. Buongiorno S. Viapiano F. Campanelli M. Ciocia A.M. De Leonardis N. Effects of Resveratrol, Curcumin and Quercetin Supplementation on Bone Metabolism—A Systematic Review Nutrients 2022 14 3519 10.3390/nu14173519 36079777 PMC9459740

93. Bottalico L. Castellaneta F. Charitos I.A. From Hydrotherapy to The Discovery of The Gut Microbiota: The Historical Gastrointestinal Health Concept Pharmacophore 2020 11 82 90

94. Inchingolo A.D. Cazzolla A.P. Di Cosola P. Greco Lucchina A. Santacroce L. Charitos I.A. Topi S. Malcangi G. Hazballa D. Scarano A. The Integumentary System and Its Microbiota between Health and Disease J. Biol. Regul. Homeost. Agents 2021 35 303 321 10.23812/21-2supp1-30 34281327

95. Nagpal R. Mainali R. Ahmadi S. Wang S. Singh R. Kavanagh K. Kitzman D.W. Kushugulova A. Marotta F. Yadav H. Gut Microbiome and Aging: Physiological and Mechanistic Insights Nutr. Healthy Aging 2018 4 267 285 10.3233/NHA-170030 29951588 PMC6004897

96. Newman H.N. Microbial Films in Nature Microbios 1974 9 247 257 4835700

97. Woodroffe R.C. Shaw D.A. Natural Control and Ecology of Microbial Populations on Skin and Hair Soc. Appl. Bacteriol. Symp. Ser. 1974 3 13 34 4612719

98. Santacroce L. Charitos I.A. Ballini A. Inchingolo F. Luperto P. De Nitto E. Topi S. The Human Respiratory System and Its Microbiome at a Glimpse Biology 2020 9 318 10.3390/biology9100318 33019595 PMC7599718

99. Lovero R. Charitos I.A. Topi S. Castellaneta F. Cazzolla A.P. Colella M. Current Views About the Link between SARS-CoV-2 and the Liver: Friends or Foe? Endocr. Metab. Immune Disord.-Drug Targets (Former. Curr. Drug Targets-Immune Endocr. Metab. Disord. 2024 24 642 650 10.2174/0118715303251985231009050626 37846575

100. Romano C. Cozzolino D. Nevola R. Abitabile M. Carusone C. Cinone F. Cuomo G. Nappo F. Sellitto A. Umano G.R. Liver Involvement During SARS-CoV-2 Infection Is Associated with a Worse Respiratory Outcome in COVID-19 Patients Viruses 2023 15 1904 10.3390/v15091904 37766310 PMC10537641

101. Milosevic I. Russo E. Vujovic A. Barac A. Stevanovic O. Gitto S. Amedei A. Microbiota and Viral Hepatitis: State of the Art of a Complex Matter World J. Gastroenterol. 2021 27 5488 5501 10.3748/wjg.v27.i33.5488 34588747 PMC8433613

102. Montagnani M. Bottalico L. Potenza M.A. Charitos I.A. Topi S. Colella M. Santacroce L. The Crosstalk between Gut Microbiota and Nervous System: A Bidirectional Interaction between Microorganisms and Metabolome Int. J. Mol. Sci. 2023 24 10322 10.3390/ijms241210322 37373470 PMC10299104

103. Inchingolo A.D. Malcangi G. Semjonova A. Inchingolo A.M. Patano A. Coloccia G. Ceci S. Marinelli G. Di Pede C. Ciocia A.M. Oralbiotica/Oralbiotics: The Impact of Oral Microbiota on Dental Health and Demineralization: A Systematic Review of the Literature Children 2022 9 1014 10.3390/children9071014 35883998 PMC9323959

104. Kim N. Yun M. Oh Y.J. Choi H.-J. Mind-Altering with the Gut: Modulation of the Gut-Brain Axis with Probiotics J. Microbiol. 2018 56 172 182 10.1007/s12275-018-8032-4 29492874

105. Liu X. Cao S. Zhang X. Modulation of Gut Microbiota-Brain Axis by Probiotics, Prebiotics, and Diet J. Agric. Food Chem. 2015 63 7885 7895 10.1021/acs.jafc.5b02404 26306709

106. Ashique S. Mohanto S. Ahmed M.G. Mishra N. Garg A. Chellappan D.K. Omara T. Iqbal S. Kahwa I. Gut-Brain Axis: A Cutting-Edge Approach to Target Neurological Disorders and Potential Synbiotic Application Heliyon 2024 10 e34092 10.1016/j.heliyon.2024.e34092 39071627 PMC11279763

107. You M. Chen N. Yang Y. Cheng L. He H. Cai Y. Liu Y. Liu H. Hong G. The Gut Microbiota-Brain Axis in Neurological Disorders MedComm 2024 5 e656 10.1002/mco2.656 39036341 PMC11260174

108. Margolis K.G. Cryan J.F. Mayer E.A. The Microbiota-Gut-Brain Axis: From Motility to Mood Gastroenterology 2021 160 1486 1501 10.1053/j.gastro.2020.10.066 33493503 PMC8634751

109. Bogusz K. Baran N. Maksymowicz M. Bielak A. Nowak A. Cywka Ł. Szwed W. Nowak A. Machowiec P. The Role of the Gut Microbiota in Pathogenesis and Treatment of Depression J. Educ. Health Sport 2023 31 61 72 10.12775/JEHS.2023.31.01.006

110. Honarpisheh P. Bryan R.M. McCullough L.D. Aging Microbiota-Gut-Brain Axis in Stroke Risk and Outcome Circ. Res. 2022 130 1112 1144 10.1161/CIRCRESAHA.122.319983 35420913 PMC9674376

111. Carabotti M. Scirocco A. Maselli M.A. Severi C. The Gut-Brain Axis: Interactions between Enteric Microbiota, Central and Enteric Nervous Systems Ann. Gastroenterol. 2015 28 203 209 25830558 PMC4367209

112. Costa M. Brookes S.J. Hennig G.W. Anatomy and Physiology of the Enteric Nervous System Gut 2000 47 (Suppl. 4) iv15 iv26 v15–iv19; discussion iv26 10.1136/gut.47.suppl_4.iv15 11076898 PMC1766806

113. Goyal R.K. Targets of Enteric Motor Neurones: Smooth Muscle Cells Gut 2000 47 (Suppl. 4) iv38 iv52 iv38–iv39; discussion iv52 10.1136/gut.47.suppl_4.iv38 11076908 PMC1766824

114. Rao M. Gershon M.D. Enteric Nervous System Development: What Could Possibly Go Wrong? Nat. Rev. Neurosci. 2018 19 552 565 10.1038/s41583-018-0041-0 30046054 PMC6261281

115. Lake J.I. Heuckeroth R.O. Enteric Nervous System Development: Migration, Differentiation, and Disease Am. J. Physiol. Gastrointest. Liver Physiol. 2013 305 G1 G24 10.1152/ajpgi.00452.2012 23639815 PMC3725693

116. Inchingolo A.D. Malcangi G. Inchingolo A.M. Piras F. Settanni V. Garofoli G. Palmieri G. Ceci S. Patano A. De Leonardis N. Benefits and Implications of Resveratrol Supplementation on Microbiota Modulations: A Systematic Review of the Literature Int. J. Mol. Sci. 2022 23 4027 10.3390/ijms23074027 35409389 PMC8999966

117. Browning K.N. Travagli R.A. Central Nervous System Control of Gastrointestinal Motility and Secretion and Modulation of Gastrointestinal Functions Compr. Physiol. 2014 4 1339 1368 10.1002/cphy.c130055 25428846 PMC4858318

118. Altaf M.A. Sood M.R. The Nervous System and Gastrointestinal Function Dev. Disabil. Res. Rev. 2008 14 87 95 10.1002/ddrr.15 18646012

119. Koenig J. Falvay D. Clamor A. Wagner J. Jarczok M.N. Ellis R.J. Weber C. Thayer J.F. Pneumogastric (Vagus) Nerve Activity Indexed by Heart Rate Variability in Chronic Pain Patients Compared to Healthy Controls: A Systematic Review and Meta-Analysis Pain Physician 2016 19 E55 E78 10.36076/ppj/2016.19.E55 26752494

120. Lotufo P.A. Valiengo L. Benseñor I.M. Brunoni A.R. A Systematic Review and Meta-Analysis of Heart Rate Variability in Epilepsy and Antiepileptic Drugs Epilepsia 2012 53 272 282 10.1111/j.1528-1167.2011.03361.x 22221253

121. Kenny B.J. Bordoni B. Neuroanatomy, Cranial Nerve 10 (Vagus Nerve) StatPearls StatPearls Publishing Treasure Island, FL, USA 2024 30725856

122. Baker E. Lui F. Neuroanatomy, Vagal Nerve Nuclei StatPearls StatPearls Publishing Treasure Island, FL, USA 2024 31424793

123. Barbas-Henry H.A. Lohman A.H. The Motor Nuclei and Primary Projections of the IXth, Xth, XIth and XIIth Cranial Nerves in the Monitor Lizard, Varanus Exanthematicus J. Comp. Neurol. 1984 226 565 579 10.1002/cne.902260409 6747035

124. Williams E.K. Chang R.B. Strochlic D.E. Umans B.D. Lowell B.B. Liberles S.D. Sensory Neurons That Detect Stretch and Nutrients in the Digestive System Cell 2016 166 209 221 10.1016/j.cell.2016.05.011 27238020 PMC4930427

125. Inchingolo A.D. Di Cosola M. Inchingolo A.M. Greco Lucchina A. Malcangi G. Pettini F. Scarano A. Bordea I.R. Hazballa D. Lorusso F. Correlation between Occlusal Trauma and Oral Microbiota: A Microbiological Investigation J. Biol. Regul. Homeost. Agents 2021 35 295 302 10.23812/21-2supp1-29 34281326

126. Stakenborg N. Gomez-Pinilla P.J. Verlinden T.J.M. Wolthuis A.M. D’Hoore A. Farré R. Herijgers P. Matteoli G. Boeckxstaens G.E. Comparison between the Cervical and Abdominal Vagus Nerves in Mice, Pigs, and Humans Neurogastroenterol. Motil. 2020 32 e13889 10.1111/nmo.13889 32476229 PMC7507132

127. Matteoli G. Boeckxstaens G.E. The Vagal Innervation of the Gut and Immune Homeostasis Gut 2013 62 1214 1222 10.1136/gutjnl-2012-302550 23023166 PMC3711371

128. Gargiulo Isacco C. Inchingolo A.D. Nguyen Cao K.D. Malcangi G. Paduanelli G. Pham Hung V. Tran Cong T. Bordea I.R. Scarano A. Laforgia A. The Bad Relationship, Osteo-Decay and Diabetes Type 2 Searching for a Link: A Literature Review J. Biol. Regul. Homeost. Agents 2021 35 253 269 10.23812/21-2supp1-26 34281323

129. Smith S.M. Vale W.W. The Role of the Hypothalamic-Pituitary-Adrenal Axis in Neuroendocrine Responses to Stress Dialogues Clin. Neurosci. 2006 8 383 10.31887/DCNS.2006.8.4/ssmith 17290797 PMC3181830

130. Chrousos G.P. Gold P.W. The Concepts of Stress and Stress System Disorders. Overview of Physical and Behavioral Homeostasis JAMA 1992 267 1244 1252 10.1001/jama.1992.03480090092034 1538563

131. Jankord R. Herman J.P. Limbic Regulation of Hypothalamo-Pituitary-Adrenocortical Function during Acute and Chronic Stress Ann. N. Y. Acad. Sci. 2008 1148 64 73 10.1196/annals.1410.012 19120092 PMC2637449

132. Oyola M.G. Handa R.J. Hypothalamic-Pituitary-Adrenal and Hypothalamic-Pituitary-Gonadal Axes: Sex Differences in Regulation of Stress Responsivity Stress 2017 20 476 494 10.1080/10253890.2017.1369523 28859530 PMC5815295

133. Abraham W.-R. Going beyond the Control of Quorum-Sensing to Combat Biofilm Infections Antibiotics 2016 5 3 10.3390/antibiotics5010003 27025518 PMC4810405

134. Mittal R. Debs L.H. Patel A.P. Nguyen D. Patel K. O’Connor G. Grati M. Mittal J. Yan D. Eshraghi A.A. Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis J. Cell. Physiol. 2017 232 2359 2372 10.1002/jcp.25518 27512962 PMC5772764

135. Bamalan O.A. Moore M.J. Al Khalili Y. Physiology, Serotonin StatPearls StatPearls Publishing Treasure Island, FL, USA 2024 31424752

136. Gao K. Mu C.-L. Farzi A. Zhu W.-Y. Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain Adv. Nutr. 2020 11 709 723 10.1093/advances/nmz127 31825083 PMC7231603

137. Zhou M. Fan Y. Xu L. Yu Z. Wang S. Xu H. Zhang J. Zhang L. Liu W. Wu L. Microbiome and Tryptophan Metabolomics Analysis in Adolescent Depression: Roles of the Gut Microbiota in the Regulation of Tryptophan-Derived Neurotransmitters and Behaviors in Human and Mice Microbiome 2023 11 145 10.1186/s40168-023-01589-9 37386523 PMC10311725

138. Deng Y. Zhou M. Wang J. Yao J. Yu J. Liu W. Wu L. Wang J. Gao R. Involvement of the Microbiota-Gut-Brain Axis in Chronic Restraint Stress: Disturbances of the Kynurenine Metabolic Pathway in Both the Gut and Brain Gut Microbes 2021 13 1 16 10.1080/19490976.2020.1869501 PMC7872056 33535879

139. Terry N. Margolis K.G. Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance Handb. Exp. Pharmacol. 2017 239 319 10.1007/164_2016_103 28035530 PMC5526216

140. Aarsland T.I.M. Instanes J.T. Posserud M.-B.R. Ulvik A. Kessler U. Haavik J. Changes in Tryptophan-Kynurenine Metabolism in Patients with Depression Undergoing ECT—A Systematic Review Pharmaceuticals 2022 15 1439 10.3390/ph15111439 36422569 PMC9694349

141. Juárez Olguín H. Calderón Guzmán D. Hernández García E. Barragán Mejía G. The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress Oxid. Med. Cell. Longev. 2016 2016 9730467 10.1155/2016/9730467 26770661 PMC4684895

142. Wang P. Niu L. Gao L. Li W.X. Jia D. Wang X.L. Gao G.D. Neuroprotective Effect of Gypenosides against Oxidative Injury in the Substantia Nigra of a Mouse Model of Parkinson’s Disease J. Int. Med. Res. 2010 38 1084 1092 10.1177/147323001003800336 20819446

143. Adrenaline and Noradrenaline Wiley Hoboken, NJ, USA 2010 978-0-470-01590-2 10.1002/9780470015902.a0001401.pub2

144. Byrne C.J. Khurana S. Kumar A. Tai T.C. Inflammatory Signaling in Hypertension: Regulation of Adrenal Catecholamine Biosynthesis Front. Endocrinol. 2018 9 343 10.3389/fendo.2018.00343 PMC6036303 30013513

145. Paravati S. Rosani A. Warrington S.J. Physiology, Catecholamines StatPearls StatPearls Publishing Treasure Island, FL, USA 2024 29939538

146. Cabana B.E. Prokesch J.C. Christiansen G.S. Study on the Biogenesis of Catecholamines in Pheochromocytoma Tissue Culture Arch. Biochem. Biophys. 1964 106 123 130 10.1016/0003-9861(64)90164-X 14217145

147. Holzer P. Farzi A. Neuropeptides and the Microbiota-Gut-Brain Axis Adv. Exp. Med. Biol. 2014 817 195 219 10.1007/978-1-4939-0897-4_9 24997035 PMC4359909

148. Dunn J. Grider M.H. Physiology, Adenosine Triphosphate StatPearls StatPearls Publishing Treasure Island, FL, USA 2024 31985968

149. Nakrani M.N. Wineland R.H. Anjum F. Physiology, Glucose Metabolism StatPearls StatPearls Publishing Treasure Island, FL, USA 2024 32809434

150. Lee J.H. Espinera A.R. Chen D. Choi K.-E. Caslin A.Y. Won S. Pecoraro V. Xu G.-Y. Wei L. Yu S.P. Neonatal Inflammatory Pain and Systemic Inflammatory Responses as Possible Environmental Factors in the Development of Autism Spectrum Disorder of Juvenile Rats J. Neuroinflamm. 2016 13 109 10.1186/s12974-016-0575-x PMC4867541 27184741

151. Mezzelani A. Landini M. Facchiano F. Raggi M.E. Villa L. Molteni M. De Santis B. Brera C. Caroli A.M. Milanesi L. Environment, Dysbiosis, Immunity and Sex-Specific Susceptibility: A Translational Hypothesis for Regressive Autism Pathogenesis Nutr. Neurosci. 2015 18 145 161 10.1179/1476830513Y.0000000108 24621061 PMC4485698

152. Silva Y.P. Bernardi A. Frozza R.L. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication Front. Endocrinol. 2020 11 25 10.3389/fendo.2020.00025 32082260 PMC7005631

153. Castro-Mejía J.L. Khakimov B. Aru V. Lind M.V. Garne E. Paulová P. Tavakkoli E. Hansen L.H. Smilde A.K. Holm L. Gut Microbiome and Its Cofactors Are Linked to Lipoprotein Distribution Profiles Microorganisms 2022 10 2156 10.3390/microorganisms10112156 36363749 PMC9699503

154. Fock E. Parnova R. Mechanisms of Blood–Brain Barrier Protection by Microbiota-Derived Short-Chain Fatty Acids Cells 2023 12 657 10.3390/cells12040657 36831324 PMC9954192

155. Kim G.-H. Shim J.-O. Gut Microbiota Affects Brain Development and Behavior Clin. Exp. Pediatr. 2022 66 274 280 10.3345/cep.2021.01550 36397259 PMC10331547

156. Di Cosola M. Cazzolla A.P. Charitos I.A. Ballini A. Inchingolo F. Santacroce L. Candida Albicans and Oral Carcinogenesis. A Brief Review J. Fungi 2021 7 476 10.3390/jof7060476 34204731 PMC8231483

157. Breit S. Kupferberg A. Rogler G. Hasler G. Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders Front. Psychiatry 2018 9 44 10.3389/fpsyt.2018.00044 29593576 PMC5859128

158. Clapp M. Aurora N. Herrera L. Bhatia M. Wilen E. Wakefield S. Gut Microbiota’s Effect on Mental Health: The Gut-Brain Axis Clin. Pract. 2017 7 987 10.4081/cp.2017.987 29071061 PMC5641835

159. Kim Y.-K. Shin C. The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Pathophysiological Mechanisms and Novel Treatments Curr. Neuropharmacol. 2018 16 559 573 10.2174/1570159X15666170915141036 28925886 PMC5997867

160. Bastiaanssen T.F.S. Cowan C.S.M. Claesson M.J. Dinan T.G. Cryan J.F. Making Sense of … the Microbiome in Psychiatry Int. J. Neuropsychopharmacol. 2019 22 37 52 10.1093/ijnp/pyy067 30099552 PMC6313131

161. Inchingolo A.D. Inchingolo A.M. Bordea I.R. Malcangi G. Xhajanka E. Scarano A. Lorusso F. Farronato M. Tartaglia G.M. Isacco C.G. SARS-CoV-2 Disease through Viral Genomic and Receptor Implications: An Overview of Diagnostic and Immunology Breakthroughs Microorganisms 2021 9 793 10.3390/microorganisms9040793 33920179 PMC8070527

162. Binda S. Tremblay A. Iqbal U.H. Kassem O. Le Barz M. Thomas V. Bronner S. Perrot T. Ismail N. Parker J.A. Psychobiotics and the Microbiota–Gut–Brain Axis: Where Do We Go from Here? Microorganisms 2024 12 634 10.3390/microorganisms12040634 38674579 PMC11052108

163. Santacroce L. Di Cosola M. Bottalico L. Topi S. Charitos I.A. Ballini A. Inchingolo F. Cazzolla A.P. Dipalma G. Focus on HPV Infection and the Molecular Mechanisms of Oral Carcinogenesis Viruses 2021 13 559 10.3390/v13040559 33810374 PMC8067023

164. Kouli A. Torsney K.M. Kuan W.-L. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis Parkinson’s Disease: Pathogenesis and Clinical Aspects Stoker T.B. Greenland J.C. Codon Publications Brisbane, Australia 2018 978-0-9944381-6-4 30702842

165. Inchingolo A.D. Inchingolo A.M. Bordea I.R. Malcangi G. Xhajanka E. Scarano A. Lorusso F. Farronato M. Tartaglia G.M. Isacco C.G. SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention Microorganisms 2021 9 525 10.3390/microorganisms9030525 33806624 PMC7999785

166. Roshan M.H.K. Tambo A. Pace N.P. Potential Role of Caffeine in the Treatment of Parkinson’s Disease Open Neurol. J. 2016 10 42 58 10.2174/1874205X01610010042 27563362 PMC4962431

167. Manfredsson F.P. Luk K.C. Benskey M.J. Gezer A. Garcia J. Kuhn N.C. Sandoval I.M. Patterson J.R. O’Mara A. Yonkers R. Induction of Alpha-Synuclein Pathology in the Enteric Nervous System of the Rat and Non-Human Primate Results in Gastrointestinal Dysmotility and Transient CNS Pathology Neurobiol. Dis. 2018 112 106 118 10.1016/j.nbd.2018.01.008 29341898 PMC5890443

168. Ma Q. Xing C. Long W. Wang H.Y. Liu Q. Wang R.F. Impact of Microbiota on Central Nervous System and Neurological Diseases: The Gut-Brain Axis J. Neuroinflamm. 2019 16 53 10.1186/s12974-019-1434-3 30823925 PMC6397457

169. Fung T.C. The Microbiota-Immune Axis as a Central Mediator of Gut-Brain Communication Neurobiol. Dis. 2020 136 104714 10.1016/j.nbd.2019.104714 31846737

170. Spielman L.J. Gibson D.L. Klegeris A. Unhealthy Gut, Unhealthy Brain: The Role of the Intestinal Microbiota in Neurodegenerative Diseases Neurochem. Int. 2018 120 149 163 10.1016/j.neuint.2018.08.005 30114473

171. Wang X. Liang Z. Wang S. Ma D. Zhu M. Feng J. Role of Gut Microbiota in Multiple Sclerosis and Potential Therapeutic Implications Curr. Neuropharmacol. 2022 20 1413 1426 10.2174/1570159X19666210629145351 34191698 PMC9881072

172. Chandra S. Alam M.T. Dey J. Sasidharan B.C. Ray U. Srivastava A.K. Gandhi S. Tripathi P.P. Healthy Gut, Healthy Brain: The Gut Microbiome in Neurodegenerative Disorders Curr. Top. Med. Chem. 2020 20 1142 1153 32282304 10.2174/1568026620666200413091101

173. Tankou S.K. Regev K. Healy B.C. Tjon E. Laghi L. Cox L.M. Kivisäkk P. Pierre I.V. Hrishikesh L. Gandhi R. A Probiotic Modulates the Microbiome and Immunity in Multiple Sclerosis Ann. Neurol. 2018 83 1147 1161 10.1002/ana.25244 29679417 PMC6181139

174. Liu L. Wang H. Chen X. Zhang Y. Zhang H. Xie P. Gut Microbiota and Its Metabolites in Depression: From Pathogenesis to Treatment EBioMedicine 2023 90 104527 10.1016/j.ebiom.2023.104527 36963238 PMC10051028

175. Borovikova L.V. Ivanova S. Zhang M. Yang H. Botchkina G.I. Watkins L.R. Wang H. Abumrad N. Eaton J.W. Tracey K.J. Vagus Nerve Stimulation Attenuates the Systemic Inflammatory Response to Endotoxin Nature 2000 405 458 462 10.1038/35013070 10839541

176. Johnston G.R. Webster N.R. Cytokines and the Immunomodulatory Function of the Vagus Nerve Br. J. Anaesth. 2009 102 453 462 10.1093/bja/aep037 19258380

177. Yao M. Qu Y. Zheng Y. Guo H. The Effect of Exercise on Depression and Gut Microbiota: Possible Mechanisms Brain Res. Bull. 2024 220 111130 39557221 10.1016/j.brainresbull.2024.111130

178. Santacroce L. Inchingolo F. Topi S. Del Prete R. Di Cosola M. Charitos I.A. Montagnani M. Potential Beneficial Role of Probiotics on the Outcome of COVID-19 Patients: An Evolving Perspective Diabetes Metab. Syndr. 2021 15 295 301 10.1016/j.dsx.2020.12.040 33484986 PMC7804381

179. Vafadari B. Stress and the Role of the Gut-Brain Axis in the Pathogenesis of Schizophrenia: A Literature Review Int. J. Mol. Sci. 2021 22 9747 10.3390/ijms22189747 34575911 PMC8471971

180. Limbana T. Khan F. Eskander N. Gut Microbiome and Depression: How Microbes Affect the Way We Think—PubMed Cureus 2020 12 e9966 32983670 10.7759/cureus.9966 PMC7510518

181. Santos J.M. Mathew M.S. Shah N. Pajuelo-Vasquez R. Mistry A.M. Heindl S.E. Pre and Post-Operative Alterations of the Gastrointestinal Microbiome Following Bariatric Surgery Cureus 2021 13 e13057 10.7759/cureus.13057 33680599 PMC7929544

182. Mosquera F.E.C. Guevara-Montoya M.C. Serna-Ramirez V. Liscano Y. Neuroinflammation and Schizophrenia: New Therapeutic Strategies through Psychobiotics, Nanotechnology, and Artificial Intelligence (AI) J. Pers. Med. 2024 14 391 10.3390/jpm14040391 38673018 PMC11051547

183. Qian X. Li Q. Zhu H. Chen Y. Lin G. Zhang H. Chen W. Wang G. Tian P. Bifidobacteria with Indole-3-Lactic Acid-Producing Capacity Exhibit Psychobiotic Potential via Reducing Neuroinflammation Cell Rep. Med. 2024 5 101798 10.1016/j.xcrm.2024.101798 39471819 PMC11604549

184. Signorini L. Ballini A. Arrigoni R. De Leonardis F. Saini R. Cantore S. De Vito D. Coscia M.F. Dipalma G. Santacroce L. Evaluation of a Nutraceutical Product with Probiotics, Vitamin D, Plus Banaba Leaf Extracts ( Lagerstroemia speciosa ) in Glycemic Control Endocr. Metab. Immune Disord. Drug Targets 2021 21 1356 1365 10.2174/22123873MTExnMjg6x 33167849

185. Szeligowski T. Yun A.L. Lennox B.R. Burnet P.W.J. The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical Applications Front. Psychiatry 2020 11 156 10.3389/fpsyt.2020.00156 32226399 PMC7080964

186. Mallah K. Couch C. Borucki D.M. Toutonji A. Alshareef M. Tomlinson S. Anti-Inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here? Front. Immunol. 2020 11 2021 10.3389/fimmu.2020.02021 33013859 PMC7513624

187. Munawar N. Ahsan K. Muhammad K. Ahmad A. Anwar M.A. Shah I. Al Ameri A.K. Al Mughairbi F. Hidden Role of Gut Microbiome Dysbiosis in Schizophrenia: Antipsychotics or Psychobiotics as Therapeutics Int. J. Mol. Sci. 2021 22 7671 10.3390/ijms22147671 34299291 PMC8307070

188. Maczurek A. Hager K. Kenklies M. Sharman M. Martins R. Engel J. Carlson D.A. Münch G. Lipoic Acid as an Anti-Inflammatory and Neuroprotective Treatment for Alzheimer’s Disease Adv. Drug Deliv. Rev. 2008 60 1463 1470 10.1016/j.addr.2008.04.015 18655815

189. Signorini L. De Leonardis F. Santacroce L. Haxhirexha K. Topi S. Fumarola L. Dipalma G. Coscia M.F. Inchingolo F. Probiotics May Modulate the Impact of Aging on Adults J. Biol. Regul. Homeost. Agents 2020 34 1601 1606 10.23812/20-393-L 32909421

190. Gîlcă-Blanariu G.-E. Șchiopu C.G. Ștefănescu G. Mihai C. Diaconescu S. Afrăsânie V.A. Lupu V.V. Lupu A. Boloș A. Ștefănescu C. The Intertwining Roads between Psychological Distress and Gut Microbiota in Inflammatory Bowel Disease Microorganisms 2023 11 2268 10.3390/microorganisms11092268 37764111 PMC10538137

191. Flowers S.A. Ward K.M. Clark C.T. The Gut Microbiome in Bipolar Disorder and Pharmacotherapy Management Neuropsychobiology 2020 79 43 49 10.1159/000504496 31722343

192. McGovern A.S. Hamlin A.S. Winter G. A Review of the Antimicrobial Side of Antidepressants and Its Putative Implications on the Gut Microbiome Aust. N. Z. J. Psychiatry 2019 53 1151 1166 10.1177/0004867419877954 31558039

193. Isacco C.G. Ballini A. De Vito D. Nguyen K.C.D. Cantore S. Bottalico L. Quagliuolo L. Boccellino M. Di Domenico M. Santacroce L. Rebalancing the Oral Microbiota as an Efficient Tool in Endocrine, Metabolic and Immune Disorders Endocr. Metab. Immune Disord. Drug Targets 2021 21 777 784 10.2174/22123873MTA4CNjQs0 32727337

194. Shanahan F. Sheehan D. Microbial Contributions to Chronic Inflammation and Metabolic Disease Curr. Opin. Clin. Nutr. Metab. Care 2016 19 257 262 10.1097/MCO.0000000000000282 27097361

195. Bundgaard-Nielsen C. Knudsen J. Leutscher P.D. Lauritsen M.B. Nyegaard M. Hagstrøm S. Sørensen S. Gut Microbiota Profiles of Autism Spectrum Disorder and Attention Deficit/Hyperactivity Disorder: A Systematic Literature Review Gut Microbes 2020 11 1172 1187 10.1080/19490976.2020.1748258 32329656 PMC7524304

196. Kurokawa S. Nomura K. Sanada K. Miyaho K. Ishii C. Fukuda S. Iwamoto C. Naraoka M. Yoneda S. Imafuku M. A Comparative Study on Dietary Diversity and Gut Microbial Diversity in Children with Autism Spectrum Disorder, Attention-Deficit Hyperactivity Disorder, Their Neurotypical Siblings, and Non-Related Neurotypical Volunteers: A Cross-Sectional Study J. Child. Psychol. Psychiatry 2024 65 1184 1195 10.1111/jcpp.13962 38562118

197. Ballini A. Dipalma G. Isacco C.G. Boccellino M. Di Domenico M. Santacroce L. Nguyễn K.C.D. Scacco S. Calvani M. Boddi A. Oral Microbiota and Immune System Crosstalk: A Translational Research Biology 2020 9 131 10.3390/biology9060131 32560235 PMC7344575

198. Curran E.A. O’Neill S.M. Cryan J.F. Kenny L.C. Dinan T.G. Khashan A.S. Kearney P.M. Research Review: Birth by Caesarean Section and Development of Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis J. Child Psychol. Psychiatry 2015 56 500 508 10.1111/jcpp.12351 25348074

199. Curran E.A. Khashan A.S. Dalman C. Kenny L.C. Cryan J.F. Dinan T.G. Kearney P.M. Obstetric Mode of Delivery and Attention-Deficit/Hyperactivity Disorder: A Sibling-Matched Study Int. J. Epidemiol. 2016 45 532 542 10.1093/ije/dyw001 27063604

200. Xu M. Yu X. Fan B. Li G. Ji X. Influence of Mode of Delivery on Children’s Attention Deficit Hyperactivity Disorder and Childhood Intelligence Psychiatry Investig. 2023 20 714 720 10.30773/pi.2022.0310 37559451 PMC10460982

201. Matthews M. Nigg J.T. Fair D.A. Attention Deficit Hyperactivity Disorder Curr. Top. Behav. Neurosci. 2014 16 235 266 10.1007/7854_2013_249 24214656 PMC4079001

202. Lange K.W. Reichl S. Lange K.M. Tucha L. Tucha O. The History of Attention Deficit Hyperactivity Disorder Atten. Deficit Hyperact. Disord. 2010 2 241 255 10.1007/s12402-010-0045-8 21258430 PMC3000907

203. Santacroce L. Sardaro N. Topi S. Pettini F. Bottalico L. Cantore S. Cascella G. Del Prete R. Dipalma G. Inchingolo F. The Pivotal Role of Oral Microbiota in Health and Disease J. Biol. Regul. Homeost. Agents 2020 34 733 737 10.23812/20-127-L-45 32492992

204. Rogliani P. Calzetta L. Coppola A. Cavalli F. Ora J. Puxeddu E. Matera M.G. Cazzola M. Optimizing Drug Delivery in COPD: The Role of Inhaler Devices Respir. Med. 2017 124 6 14 10.1016/j.rmed.2017.01.006 28284323

205. Ahmad S.I. Owens E.B. Hinshaw S.P. Little Evidence for Late-Onset ADHD in a Longitudinal Sample of Women J. Consult. Clin. Psychol. 2019 87 112 117 10.1037/ccp0000353 30570306 PMC6610733

206. Agnew-Blais J.C. Polanczyk G.V. Danese A. Wertz J. Moffitt T.E. Arseneault L. Evaluation of the Persistence, Remission, and Emergence of Attention-Deficit/Hyperactivity Disorder in Young Adulthood JAMA Psychiatry 2016 73 713 720 10.1001/jamapsychiatry.2016.0465 27192174 PMC5475268

207. Kuddo T. Nelson K.B. How Common Are Gastrointestinal Disorders in Children with Autism? Curr. Opin. Pediatr. 2003 15 339 343 10.1097/00008480-200306000-00020 12806268

208. Pulikkan J. Mazumder A. Grace T. Role of the Gut Microbiome in Autism Spectrum Disorders Adv. Exp. Med. Biol. 2019 1118 253 269 10.1007/978-3-030-05542-4_13 30747427

209. Luna R.A. Savidge T.C. Williams K.C. The Brain-Gut-Microbiome Axis: What Role Does It Play in Autism Spectrum Disorder? Curr. Dev. Disord. Rep. 2016 3 75 81 10.1007/s40474-016-0077-7 27398286 PMC4933016

210. Oh D. Cheon K.-A. Alteration of Gut Microbiota in Autism Spectrum Disorder: An Overview J. Korean Acad. Child Adolesc. Psychiatry 2020 31 131 145 10.5765/jkacap.190039 32665757 PMC7350540

211. Gilbert J.A. Blaser M.J. Caporaso J.G. Jansson J.K. Lynch S.V. Knight R. Current Understanding of the Human Microbiome Nat. Med. 2018 24 392 400 10.1038/nm.4517 29634682 PMC7043356

212. Chuong K.H. Mack D.R. Stintzi A. O’Doherty K.C. Human Microbiome and Learning Healthcare Systems: Integrating Research and Precision Medicine for Inflammatory Bowel Disease Omics J. Integr. Biol. 2018 22 119 126 10.1089/omi.2016.0185 28282257 PMC5810428

213. Wang Q. Yang Q. Liu X. The Microbiota-Gut-Brain Axis and Neurodevelopmental Disorders Protein Cell 2023 14 762 775 10.1093/procel/pwad026 37166201 PMC10599644

214. Sha C. Jin Z. Ku S.Y. Kogosov A.S. Yu S. Bergese S.D. Hsieh H. Necrotizing Enterocolitis and Neurodevelopmental Impairments: Microbiome, Gut, and Brain Entanglements Biomolecules 2024 14 1254 10.3390/biom14101254 39456187 PMC11505939

215. Lu J. Martin C.R. Claud E.C. Neurodevelopmental Outcome of Infants Who Develop Necrotizing Enterocolitis: The Gut-Brain Axis Semin. Perinatol. 2023 47 151694 10.1016/j.semperi.2022.151694 36572620 PMC9974904

216. Kaminski V.d.L. Michita R.T. Ellwanger J.H. Veit T.D. Schuch J.B. Riesgo R.D.S. Roman T. Chies J.A.B. Exploring Potential Impacts of Pregnancy-Related Maternal Immune Activation and Extracellular Vesicles on Immune Alterations Observed in Autism Spectrum Disorder Heliyon 2023 9 e15593 10.1016/j.heliyon.2023.e15593 37305482 PMC10256833

217. Njotto L.L. Simin J. Fornes R. Odsbu I. Mussche I. Callens S. Engstrand L. Bruyndonckx R. Brusselaers N. Maternal and Early-Life Exposure to Antibiotics and the Risk of Autism and Attention-Deficit Hyperactivity Disorder in Childhood: A Swedish Population-Based Cohort Study Drug Saf. 2023 46 467 478 10.1007/s40264-023-01297-1 37087706 PMC10164008

218. Avó-Baião R. Vareda R. Lopes A. Comment on: “Maternal and Early-Life Exposure to Antibiotics and the Risk of Autism and Attention-Deficit Hyperactivity Disorder in Childhood: A Swedish Population-Based Cohort Study” Drug Saf. 2024 47 821 822 10.1007/s40264-024-01464-y 38967836

219. Oberlander T.F. Zwaigenbaum L. Disentangling Maternal Depression and Antidepressant Use During Pregnancy as Risks for Autism in Children JAMA 2017 317 1533 1534 10.1001/jama.2017.3414 28418464

220. Tran S.M.-S. Mohajeri M.H. The Role of Gut Bacterial Metabolites in Brain Development, Aging and Disease Nutrients 2021 13 732 10.3390/nu13030732 33669008 PMC7996516

221. Inchingolo F. Santacroce L. Cantore S. Ballini A. Del Prete R. Topi S. Saini R. Dipalma G. Arrigoni R. Probiotics and EpiCor® in Human Health J. Biol. Regul. Homeost. Agents 2019 33 1973 1979 10.23812/19-543-L 31858774

222. Markowiak P. Śliżewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health Nutrients 2017 9 1021 10.3390/nu9091021 28914794 PMC5622781

223. Johnson D. Letchumanan V. Thurairajasingam S. Lee L.-H. A Revolutionizing Approach to Autism Spectrum Disorder Using the Microbiome Nutrients 2020 12 1983 10.3390/nu12071983 32635373 PMC7400420

224. Contaldo M. Lucchese A. Lajolo C. Rupe C. Di Stasio D. Romano A. Petruzzi M. Serpico R. The Oral Microbiota Changes in Orthodontic Patients and Effects on Oral Health: An Overview J. Clin. Med. 2021 10 780 10.3390/jcm10040780 33669186 PMC7919675

225. Arrigoni R. Ballini A. Santacroce L. Cantore S. Inchingolo A. Inchingolo F. Di Domenico M. Quagliuolo L. Boccellino M. Another Look at Dietary Polyphenols: Challenges in Cancer Prevention and Treatment Curr. Med. Chem. 2022 29 1061 1082 10.2174/0929867328666210810154732 34375181

226. Zhang J. Zhu G. Wan L. Liang Y. Liu X. Yan H. Zhang B. Yang G. Effect of Fecal Microbiota Transplantation in Children with Autism Spectrum Disorder: A Systematic Review Front. Psychiatry 2023 14 1123658 10.3389/fpsyt.2023.1123658 36937721 PMC10017995

227. Ballini A. Paduanelli G. Inchingolo A. Nguyen K.C. Inchingolo A.M. van Pham H. Aityan S. Schiffman M. Tran T. Duy Huynh T. Bone Decay and beyond: How Can We Approach It Better J. Biol. Regul. Homeost. Agents 2019 33 143 154 32425035

228. Li Y. Xiao P. Cao R. Le J. Xu Q. Xiao F. Ye L. Wang X. Wang Y. Zhang T. Effects and Microbiota Changes Following Oral Lyophilized Fecal Microbiota Transplantation in Children with Autism Spectrum Disorder Front. Pediatr. 2024 12 1369823 10.3389/fped.2024.1369823 38783921 PMC11112010